**Table F-1. Clinician administered PTSD scales, self-administered PTSD scales, remission, and loss of PTSD diagnosis**

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Acarturk et al., 2016[44](#_ENREF_44) | G1: EMDR-R-TEP  G2: WL | HTQ  Mean (SE at pre-tx; SD at post-tx and followup)  G1 Pre-tx:2.63 (13.65)  G1 Post-tx: 1.42 (0.07)  G1 1 month FU: 1.57 (0.08)  G2 Pre-tx: 2.47 (0.43)  G2 Post-tx: 2.38 (0.08)  G2 1 month FU: 2.38 (0.08)  G1 vs G2 pre to post-tx p<0.001  G1 vs G2 pre-tx to FU, p<0.001  Treatment X Time, F = 1.33, p = 0.254 from post-tx to FU  Mean estimated difference, post-tx: -0.96 (95% CI, -1.18 to -0.74), p <0.001  Mean estimated difference, 1 month FU: -0.81 (95% CI, -1.04 to -0.58),  p <0.001 | IES-R  Mean (SE at pre-tx; SD at post-tx and followup)  G1 Pre-tx:59.69 (13.65)  G1 Post-tx:21.36 (2.76)  G1 1 month FU: 25.87 (3.01)  G2 Pre-tx: 62.55 (12.46)  G2 Post-tx: 59.01 (2.92)  G2 1 month FU: 60.37 (3.01)  G1 vs G2 pre to post-tx p<0.001  G1 vs G2 pre-tx to FU p<0.001  Treatment X Time, F = 0.50, p = 0.483 from post-tx to FU  Mean estimated difference, post-tx: -37.65 (95% CI, -45.66 to 29.63), p <0.001  Mean estimated difference, 1 month FU: -34.50 (95% CI, -43.25 to -25.76),  p <0.001 | Remission NR  Loss of Diagnosis based on MINI PTSD, n (%)  G1 Post-tx: 30 (61)  G2 Post-tx: 3 (6)  X2 (df) = 33.31 (1), p <0.001  OR = 24.21 (95% CI, 6.59 to 88.98)  NNT=2 (95%CI, 1.4-2.5)  G1 1 month followup: 24 (49)  G2 1 month followup: 2 (4)  X2 (df) = 25.34 (1), p <0.001  X2 (df) = 25.34 (1), p <0.001  OR = 22.56 (95% CI, 4.92 to 103.35)  NNT=3 (95% CI, 1.9-5.7) |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Acosta et al., 2017[149](#_ENREF_149) | G1: Web CBT plus TAU (Thinking Forward and usual VA primary care services)  G2: TAU, usual VA primary care services | NR | PCL  Treatment by time interaction effect, NS for PTSD severity and PTSD symptoms during in-treatment period, Estimate: -0.09 (0.50)  Treatment by time effect, NS for PTSD severity and PTSD symptoms contrasting in and post treatment period (period between post treatment and 3 month followup), Estimate: 0.40 (0.82) | Remission  Clinically meaningful improvement on PCL PTSD symptoms (i.e., >10-point decrease)  12 weeks  G1:41.0%  G2: 31.3%  Chi-square, NS  3-month followup  G1: 37.5%  G2: 29.7%  Chi-square, NS  No longer reporting clinical levels of distress based on PCL distress (i.e., >50)  12 weeks  G1: 22.2%  G2: 17.9%  Chi-square, NS  3-month followup  G1: 17.9%  G2: 23.4%  Chi-square, NS  Loss of Diagnosis: NR |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Akuchekian et al., 2004[77](#_ENREF_77) | G1: Topiramate  25 to 500 mg/day (sensitive patients started at 12.5mg/day)  G2: Placebo | CAPS Mean (SD) G1 Pre-tx: 50.70 (7.7) G1 Post-tx: 32.75 (8.2)  G2 Pre-tx: 48.9 (9.13) G2 Post-tx: 46.62 (8.8)  G1 vs. G2, p=0.00 (based on t-test) | NR | NR  NR |
| Asukai et al., 2010[10](#_ENREF_10) | G1: CBT, exposure-based therapy  G2: UC | CAPS Adjusted Mean (SE)  G1 Pre-tx:84.58 (7.78)  G1 Post-tx: 43.76 (8.43)  G2 Pre-tx:84.33 (7.78)  G2 Post-tx: 84.81 (7.96)  At post: G1 vs. G2=  p<0.01(based on t-test) | IES-R  Adjusted Means (SE)  G1 Pre-tx: 59.67 (5.06)  G1 Post-tx: 21.15 (5.53)  G2 Pre-tx: 59.75 (5.06)  G2 Post-tx: 53.75 (5.20)  At post: G1 vs. G2 = p<0.001 (based on t-test) | NR  NR |
| Bartzokis et al., 2005[86](#_ENREF_86) | G1: Risperidone  1 to 3 mg/day  G2: Placebo | CAPS Unadjusted Change from baseline (SD) G1: -14.3 (16.7) G2: -4.6 (13.2)  G1 vs. G2, p<0.05 | NR | NR  NR |
| Basoglu et al., 2007[11](#_ENREF_11) | G1: CBT, exposure-based therapy  G2: WL | CAPS Mean (SD) G1 Pre-tx: 63.1 (10.1) G1 Week 4: 38.7 (18.7) G1 Week 8:30.2 (20.3)   G2 Pre-tx: 62.3 (14.5) G2 Week 4: 54.5 (16.9) G2 Week 8: 49.1 (20.3)  G1 vs. G2 at Week 4, p<0.01  G1 vs. G2 at Week 8, p<0.01 | NR | NR  NR |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Batki et al., 2014[165](#_ENREF_165) | G1: Topiramate  25 to 300mg  G2: Placebo | NR | PCL total  Between-group analysis  Weeks 1 to 12 Avg.  G1: 42.3 (16.0)  G2: 49.0 (16.5)  P p = 0.100, IRR = -9.01, 95% CI -19.8-1.80, % diff. = 14  Main Effects of treatment, F (1,48) = 2.81, p = 0.100 | Remission NR  Loss of PTSD diagnosis NR |
| Becker et al., 2007[183](#_ENREF_183) | G1: Bupropion  100 to 300 mg/day  G2: Placebo | CAPS  Within-Group Mean Change (SD)(Baseline-Endpoint) G1: 12.33 (24.12)  G2: 16.99 (11.26)  Group effect, p<0.01 | DTS  Within-Group Mean Change (SD)(Baseline-Endpoint)  G1: 13.22 (21.62)  G2: 10.6 (29.20)    Group effect, p<0.05 | NR  NR |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Blanchard et al., 2003[36](#_ENREF_36) | G1: CBT-mixed  G2: Supportive psychotherapy  G3: WL | CAPS  Mean (SD)  G1 Pre-tx: 68.2 (22.7)  G1 Post-tx: 23.7 (26.2)  G2 Pre-tx: 65.0 (25.9)  G2 Post-tx:40.1 (25.7)  G3 Baseline: 65.8 (26.6)  G3 Post-tx: 54.0 (25.9)  Group X Time at post-tx, p<0.001  G1 vs. G2, p=0.002  G1 vs. G3, p<0.001  G2 vs. G3, p=0.012  Including Dropouts  Group X Time at post-tx, p<0.001  G1 vs. G2, p=0.013  G1 vs. G3, p<0.001  G2 vs. G3, p=0.052  Group X Time, 3 mth FU  p=0.048  G1 continued to have lower scores than G2, p=0.003  Decreases from post-tx to the 3 mth fu, NS | IES  Mean (SD)  G1 Baseline: 40.4 (13.8)  G1 Post-tx: 12.1 (14.9)  G1 FU: 12.2 (13.6)  G2 Baseline: 38.7 (20.9)  G2 Post-tx: 27.4 (19.1)  G2 FU: 24.0 (20.1)  G3 Baseline:40.2 (15.9)  G3 Post-tx: 36.6 (17.2)  Post-tx  G1 vs. G2 & G3, p<0.01  G2 vs. G3, NS  PCL  Mean (SD)  G1 Baseline: 54.4 (12.2)  G1 Post-tx: 31.3 (14.1)  G1 FU: 31.1 (14.2)  G2 Baseline: 55.0 (14.7)  G2 Post-tx: 43.8 (14.6)  G2 FU: 40.8 (14.4)  G3 Baseline: 55.9 (13.3)  G3 Post-tx: 53.9 (14.1)  Post-tx  G1 vs. G2 & G3, p<0.01  G2 vs. G3, significantly greater change | NR  Improved from PTSD to sub-syndromal PTSD or non-PTSD  G1: 76.2%  G2: 47.6  G3: 23.8%  3 month FU  G1: 81%  G2: 42.9% |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Boden et al., 2012[58](#_ENREF_58) | G1: Seeking Safety and TAU  G2: TAU | NR | IES-R  Mean (SD)  G1 Pre-tx: 46.8 (19.5)  G1 Post-tx: 40.8 (20.9)  G1 6 mth FU: 38.9 (16.7)  G2 Pre-tx: 47.4 (16.3)  G2 Post-tx: 42.4 (21.3)  G2 6 mth FU: 36.5 (16.9)  Between Group Differences, NS  G1 Within-Group Differences  Pre-tx vs. 6mth FU, p<0.05  G2 Within-Group Differences Pre-tx vs. 6mth, p<0.05  G2 Within-Group Differences Post-tx vs. 6 mth FU, p<0.05 | NR  NR |
| Bohus et al., 2013[23](#_ENREF_23) | G1: DBT-PTSD  G2: TAU-WL | CAPS  Mean (SD)  G1 Pre-tx: 87.92 (14.20)  G1 Post-tx: 60.31(26.76)  G1 18 week followup: 57.47 (25.66)  G1 24 week followup: 58.50 (24.20)  G2 Pre-tx: 82.63 (18.20)  G2 Post-tx: 83.53 (16.50)  G2 18 week followup: 79.74 (21.67)  G2 24 week followup: 80.21 (19.21)  Hedges’ g between group: 1.35  Treatment X Time Interaction: -1.138 (0.195), p<0.001 | PDS  Mean (SD)  G1 Pre-tx: 2.22 (0.44)  G1 Post-tx: 1.61 (0.64)  G1 18 week followup: 1.53 (0.55)  G1 24 week followup: 1.53 (0.65)  G2 Pre-tx: 2.09 (0.45)  G2 Post-tx: 2.09 (0.46)  G2 18 week followup: 2.05 (0.47)  G2 24 week followup: 2.00 (0.42)  Hedges’ g between group: 1.00  Treatment X Time Interaction: -0.021 (0.006), p<0.001 | Remission: NR  Loss of Diagnosis at 12 weeks weeks (not meeting DSM-IV PTSD criteria any longer according to the CAPS)  G1: 14 (38.9%)  G2: 4 (10.5%)  p=0.0018  Borderline Personality Disorder Subgroup  G1: 7 (41.2%)  G2: 0 (0.0%)  p=0.0058 |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Brady et al., 2000[66](#_ENREF_66) | G1: Sertraline  25 to 200 mg/day  G2: Placebo | CAPS-2  Mean change (SEM) G1: -33.0 (2.8) G2: -23.2 (2.9) Difference Between Mean Change (95% CI): 9.8 (1.8 to 17.7), p=0.02 | IES  Mean Change (SEM)  G1: -16.2 (1.6)  G2: -12.1 (1.6)  Difference Between Mean Change (95% CI):  4.1 (-0.4 to 8.7), p=0.07  DTS  Mean Change (SEM)  G1: -28.1 (2.8)  G2: -16.1(2.8)  G1 vs. G2 p=0.003 | NR  NR |
| Brady et al., 2005[67](#_ENREF_67) | G1: Sertraline  150 mg/day  G2: Placebo | CAPS ANCOVA F (2, 68) = 2.68, p=0.08 | IES  Authors reported 'no significant difference between groups' (data NR) | NR  NR |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Bryant et al., 2003[41](#_ENREF_41) | G1: CBT, exposure based therapy (Prolonged Imaginal Exposure)  G2: CBT-Mixed  Prolonged Imaginal Exposure plus Cognitive Restructuring  G3: Supportive Control | CAPS-Intensity Mean (SD) G1 Pre-tx: 32.50 (8.71)  G1 Post-tx: 19.15 (11.15) G1 6 mth FU: -20.70 (12.00)  G2 Pre-tx: 32.70 (7.51)  G2 Post-tx: 15.90 (13.36) G2 6 mth FU: 15.70 (14.79)  G3 Pre-tx: 32.83 (8.01)  G3 Post-tx: 28.00 (15.31) G3 6 mth FU: 30.28 (12.89)  Post-tx, p<0.01 (main effects)  FU, p<0.05 (main effects)  CAPS-Frequency (CAPS-F)  Mean (SD)  G1 Pre-tx: 36.80 (9.82)  G2 Post-tx: 20.55 (12.73)  G1 6 mth FU: 23.25 (12.90)  G2 Pre-tx: 36.00 (8.69)  G2 Post-tx:17.20 (15.62)  G2 6 mth FU: 17.00 (15.22)  G3 Pre-tx: 38.33 (9.64)  G3 Post-tx: 30.00 (16.42)  G3 6 mth FU: 32.44 (13.57)  Post-tx, p<0.01 (main effects)  FU, p<0.05 (main effects) | IES-Intrusions  Mean (SD)  G1 Pre-tx: 23.85 (7.07)  G1 Post-tx: 17.65 (7.34)  G1 6 mth FU: 17.60 (9.88)  G2 Pre-tx: 26.60 (7.02)  G2 Post-tx:15.10 (12.86)  G2 6 mth FU: 15.95 (12.18)  G3 Pre-tx: 28.44 (6.60)  G3 Post-tx: 15.10 (12.86)  G3 6 mth FU: 25.44 (7.79)  Post-tx, p<0.01 (main effects)  FU, p<0.05 (main effects)  IES-Avoidance  Mean (SD)  G1 Pre-tx: 26.40 (6.65)  G1 Post-tx: 19.45 (13.48)  G1 6 mth FU: 20.75 (12.66)  G2 Pre-tx: 26.40 (6.65)  G2 Post-tx: 16.15 (13.49)  G2 6 mth FU: 14.95 (12.32)  G3 Pre-tx: 26.17 (8.95)  G3 Post-tx: 25.50 (9.54)  G3 6 mth FU: 24.78 (9.55)  Post-tx, p<0.01 (main effect)  FU, p<0.05 (main effect) | NR  No longer met criteria for PTSD at Posttreatment  G1: 50.0%  G2: 65.0%  G3: 33.0%  p(G2/G3) <0.05  No longer met criteria for PTSD at 6 month followup  G1: 50.0%  G2: 60.0%  G3: 22.0%  p(G1/G3) <0.07  p(G2/G3) <0.05 |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Bryant et al., 2008[42](#_ENREF_42) | G1: CBT, exposure based (Imaginal Exposure)  G2: CBT, exposure-based therapy (In vivo exposure)  G3: CBT, exposure-based therapy (Imaginal Exposure/In vivo Exposure)  G4: CBT-mixed  Imaginal Exposure/In vivo Exposure/ cognitive restructuring | CAPS Mean (SD) G1 Pre-tx: 73.29 (18.82)  G1 Post-tx: 55.50 (33.83)  G1 6 mth FU: 59.94 (32.36)  G2 Pre-tx: 76.79 (15.53)  G2 Post-tx: 55.96 (24.56)  G2 6 mth FU: 59.32 (29.62)  G3 Pre-tx: 76.06 (19.19)  G3 Post-tx: 55.39 (37.45)  G3 6 mth FU: 56.39 (35.87)  G4 Pre-tx: 71.35 (17.28)  G4 Post-tx: 29.86 (27.11) G4 6 mth FU: 32.86 (27.44)  Post-tx, p<0.01 (main effect)  6 mth FU, p<0.005 (main effect) | IES-Intrusions, Mean (SD) G1 Pre-tx: 24.48 (7.56)  G1 Post-tx:19.94 (8.62) G1 6 mth FU: 20.87 (10.40)  G2 Pre-tx: 24.21 (10.55)  G2 Post-tx:17.25 (11.83) G2 6 mth FU: 19.21 (12.58)  G3 Pre-tx: 27.58 (8.72)  G3 Post-tx: 20.81 (13.17)  G3 6 mth FU: 23.05 (12.14)  G4 Pre-tx: 24.89 (8.01)  G4 Post-tx: 14.07 (10.58)  G4 6 mth FU: 13.35 (11.01)  Post-tx, NS (main effect)  6 month FU, p<0.05 (main effect)  IES-Avoidance, Mean (SD) G1 Pre-tx: 29.10 (6.03)  G1 Post-tx: 20.58 (11.52) G1 6 mth FU: 21.13 (10.56)  G2 Pre-tx: 22.68 (10.52)  G2 Post-tx:17.54 (12.29) G2 6 mth FU: 17.57 (10.85)  G3 Pre-tx: 27.61 (8.50)  G3 Post-tx: 21.81 (14.31) G3 6 mth FU: 25.16 (15.14)  G4 Pre-tx: 23.71 (8.63)  G4 Post-tx:13.14 (11.00) G4 6 mth FU: 13.18 (12.58)  Post-tx, NS (main effect)  6 month FU, p<0.05 (main effect) | NR  No PTSD at Posttreatment (Based on CAPS)  G1: 37.0%  G2: 35.0%  G3: 41.0%  G4: 65.0%  p<0.10  No PTSD at 6 month followup (Based on CAPS)  G1: 25.0%  G2: 31.0%  G3: 37.0%  G4: 69.0%  p<0.01 |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Butterfield et al., 2001[82](#_ENREF_82) | G1: Olanzapine  5 to 20mg/day  G2: Placebo | SIP  Mean (SD)  G1 Pre-tx: 39.7 (9.7)  G1 Post-tx: 19.2 (8.7)  G2 Pre-tx: 45.9 (8.2)  G2 Post-tx: 17.0 (17.5)  TOP-8  Mean (SD)  G1 Pre-tx: 19.3 (4.2)  G1 Post-tx: 12.6 (6.4)  G2Baseline: 21.8 (3.3)  G2 Post-tx: 10.5 (8.7)  SPRINT - Mean (SD)  G1 Pre-tx: 31.5 (5.7)  G2 Post-tx: 17.9 (7.8)  G2 Pre-tx: 34.8 (2.1)  G2 Post-tx: 20.5 (11.1) | DTS  Mean (SD)  G1 Pre-tx: 91.6 (25.4)  G1 Post-tx: 57.4 (35.6)  G2 Pre-tx: 95.8 (16.7)  G2 Post-tx: 56.0 (36.6)  G1 vs. G2, no group X time differences found | NR  NR |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Carey et al., 2012[81](#_ENREF_81) | G1: Olanzapine  5 to 10mg  G2: Placebo | CAPS  Mean (SD)  G1 Pre-tx: 79.4 (16)  G1 Post-tx 4 week: 49.1 (27.2)  G1 Post-tx 8 week: 33.6 (28.2)  % CAPS score reduced: 57.7%  G2 Pre-tx: 81.6 (11.3)  G2 Post-tx 4 week: 73.21 (20.5)  G1 G2 Post-tx 8 week: 62.3 (31.9)  % CAPS score reduced: 23.7%  Week 4 G1 vs G2, p = 0.014  Week 8 G1 vs. G2, p = 0.018, Effect size, r = 0.43  Response (>50% reduction in CAPS score)  G1: 71%  G2: 21% | DTS  Mean (SD)  G1 Pre-tx: 75 (16.3)  G1 Post-tx 4 week: 54.8 (27.7)  G1 Post-tx 8 week 8: 37.9 (32)  % CAPS score reduced: 51%  G2 Pre-tx: 88.1 (22.5)  G2 Post-tx 4 week: 86.2 (22.3)  G1 Post-tx 8 week: 75.8 (34.5)  % CAPS score reduced: 16%  Week 4 G1 vs G2, p = 0.003  Week 8 G1 vs. G2, p = 0.006, Effect size, r = 0.5 | CGI severity  Mean (SD)  G1 Pre-tx: 4.7 (0.8)  G1 Post-tx 8 week: 2.9 (1.4)  G2 Pre-tx: 5 (0.8)  G1 Post-tx 8 week: 4.1 (1.3)  Week 8 G1 vs. G2, p = 0.027, Effect size, r = 0.4  Response (CGI improvement scale=much or very much improved)  G1: 11 (78.6%)  G2: 4 (28.6%)  Loss of PTSD diagnosis NR |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Carlson et al., 1998[46](#_ENREF_46) | G1: EMDR  G2: CBT, coping skills therapy (Biofeedback and general relaxation)  G3: WL | CAPS - Frequency  Mean (SD) G1 Pre-tx: 2.5 (0.5)  G1 3 mth FU: 0.7 (0.6)  G2 Pre-tx: 2.6 (0.5)  G2 3 mth FU: 2.0 (0.7)  G3 Pre-tx: 2.4 (0.6)  NR  Group X Time, p<0.0004  CAPS Total - Intensity: Mean(SD) G1 Pre-tx: 2.4 (0.7)  G1 3 mth FU: 0.8 (0.7)  G2 Pre-tx: 2.4 (0.5)  G2 3 mth FU: 2.0 (0.5)  G3 Pre-tx: 2.5 (0.6)  NR  Group X Time, p<0.002  CAPS Total - Overall Mean Change (SD) at 9 months G1: 36.9 (28.6) G2: 67.8 (24.7) p<0.05 | IES Total  Mean (SD)  G1 Pre-tx: 52.5 (9.0)  G1 Post-tx: 35.2 (22.0)  G1 3 mth: 29.1 (22.0)  G1 9 mth: 34.8 (28.0)  G2 Pre-tx: 52.9 (9.3)  G2 Post-tx: 44.5 (17.4)  G2 3 mth: 45.7 (15.0)  G2 9 mth: 47.0 (23.0)  G3 Pre-tx: 52.8 (11.5)  G3 Post-tx: 38.7 (16.2)  Post-tx & 3 mth FU, Group X Time, p=NS  9 month FU, p<0.24 (t-test)  MISS  Mean (SD)  G1 Pre-tx: 117.5 (14.3)  G1 Post-tx: 92.8 (20.8)  G1 3 mth: 92.4 (17.2)  G1 9 mth: 97.8 (29.8)  G2 Pre-tx: 119.4 (18.3)  G2 Post-tx: 114.2 (17.5)  G2 3 mth: 110.6 (18.6)  G1 9 mth: 127.0 (12.4)  G3 Pre-tx: 117.9 (17.6)  G3 Post-tx: 112.9 (21.7) | NR  PTSD diagnosis by CAPS at 3 months followup:  G1: 77.8% (7 of 9)  G2: 22.2% (2 of 9) |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Carlson et al., 1998[46](#_ENREF_46)  (continued) |  |  | Group X Treatment, p<0.006  G1 vs. G3, p<0.05 (post-tx)  G1 vs. G2, p<0.05 (post-tx & followup)  3 month FU,  p<0.05 (t-test)  9 month FU, p<0.05 (t-test) |  |
| Chard et al., 2005[2](#_ENREF_2) | G1: CBT, cognitive processing therapy  CPT-SA  G2: WL | CAPS-SX G1 Pre-tx: 65.46 (26.39) G1 Post-tx: 9.00 (11.04)  G2 Pre-tx 68.30 (23.67) G2 Post-tx: 62.96 (30.68)  p<0.001 (interaction) | MPSS  Mean (SD)  G1 Pre-tx: 57.57 (22.85)  G1 Post-tx: 7.54 (9.51)  G2 Pre-tx: 57.52 (24.74)  G2 Post-tx: 57.70 (27.47)  p<0.001 (interaction) | NR  No longer met PTSD criteria based on CAPS-SX at Posttreatment  G1: 93%  G2: 26%  p<0.001 |
| Church et al., 2013[155](#_ENREF_155) | G1: EFT, Emotional Freedom Techniques (brief exposure therapy combining cognitive and somatic elements, on PTSD and psychological distress symptoms in veterans) G2: WL | NR | PCL-M  Mean (SE)  G1 Pre-tx: 62.01 (2.1)  G1 Post-tx: 39.41 (2.7)  G2 Pre-tx: 62.71 (2.3)  G2 Post-tx: 63.23 (2.0)  Treatment X Time Interaction, <0.0001 | NR  NR |
| Cloitre et al., 2002[37](#_ENREF_37) | G1: CBT, exposure-based therapy(STAIR)  G2: WL | CAPS  Mean (SD) G1 Pre-tx:69 (16.3)  G1 Post-tx: 31 (25.2)  G2 Pre-tx:69 (16.6)  G2 Post-tx:62 (22.7)  p<.01 (interaction) | MPSS-SR  Mean (SD) G1 Pre-tx: 69 (16.6)  G1 Post-tx: 29 (27.6)    G2 Pre-tx:73 (18.6)  G2 Post-tx:58 (28.6)  p<0.01 (interaction) | NR  NR |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Cloitre et al., 2010[148](#_ENREF_148) | G1: CBT-Mixed  (STAIR) + PE  G2: CBT-Mixed  (STAIR) + Support (Skills Training)  G3: Support (Skills Training) + PE | CAPS Mean (SD) G1 Pre-tx:63.08 (18.29)  G1 Post-tx: 32.70 (19.37)  G1 3 mth FU:24.66 (18.47)  G1 6 mth FU:20.44 (19.01)  G2 Pre-tx: 64.34 (21.15)  G2 Post-tx: 32.32 (23.04)  G2 3 mth FU:31.88 (22.98)  G2 6 mth FU:32.51 (22.69)  G3 Pre-tx: 64.50 (15.86) G3 Post-tx: 39.72 (18.34)  G3 3 mth FU: 39.71 (17.59)  G3 6 mth FU: 28.56 (21.00)  Group X Time  G1 vs. G3 at 3 mths, p=0.01  No other contrasts significant | PSS-SR  Mean (SD) G1 Pre-tx e:36.7 (12.87)  G1 Post-tx: 14.0 (11.46)  G1 3 mth FU:12.5 (11.41)  G1 6 mth FU: 8.9 (9.83)  G2 Pre-tx:39.9 (12.65)  G2 Post-tx: 14.5 (12.79)  G2 3 mth FU:17.3 (10.10)  G2 6 mth FU: 13.7 (13.64)  G3 Pre-tx: 38.2 (11.14)  G3 Post-tx: 19.0 (9.83)  G3 3 mth FU:21.4 (11.54)  G3 6 mth FU: 20.5 (13.56)  p=0.03(interaction)  G1 pre vs. G1 post: p<0.001 G1 pre vs. G1 3 mon: p<0.001 G1 post to G1 6 mon: p<0.001 | PTSD-negative @ posttreatment  G1: 61% G2: 47%  G3: 33% p=0.11  Persistence of PTSD-negative status (maintained their status through the 3-month and 6-months assessments) G1: 55%  G2: 37%  G3: 21% p=0.03 G1 vs G3: p=0.01  OR (95% CI):4.23 (1.42–12.59)  CAPS score <20 at posttreatment  G1: 27%  G2: 24%  G3: 6%  p=0.04  Remission Rate: (Pairwise analyses)  G1 vs. G3: p=0.04  OR (95% CI): 5.67 (1.11–28.81).  The rate of sustained PTSD full remission differed among the three groups  G1: 24%,  G2: 13%  G3: 0%  p=0.002 |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Coffey et al., 2016[140](#_ENREF_140) | G1: Modified PE+ Motivational enhancement therapy (met-ptsd),  G2: PE as described in G1 without MET, relaxation prior to PE therapy.  G3: HLS, relaxation prior to PE therapy | NR | IES-R  Mean (95% CI) G1 Pre-tx: 54.95 (49.51 to 60.39)  G1 Post-tx: 20.49 (14.77 to 26.20) (p= 0.04)  G1 3 month followup: 19.10(13.01 to 25.18) (p = 0.03)  G1 6 month followup: 20.48 (14.53 to 26.42) (p < 0.05)  G2 Pre-tx: 48.56 (43.43 to 53.68)  G2 Post-tx: 16.20 (10.48 to 21.92) (p = 0.008)  G2 3 month followup: 14.11(8.33 to 19.90) (p = 0.02)  G2 6 month followup: 16.45 (10.85 to 22.06) (p = 0.13)  G3 Pre-tx: 51.02 (45.65 to 56.60) G3 Post-tx: 27.40 (21.80 to 33.01)  G3 3 month followup: 26.00 (20.15 to 31.85)  G3 6 month followup: 26.50 (20.52 to 32.50) \*p-values in parentheses denote the treatment in comparison with G3  Treatment x time interaction, post-tx: X2 = 7.25, p = 0.03  Difference in score reduction at post-tx, G1 vs. G2, p = 0.55  Treatment X Time Interaction, followup: X2 = 0.32, p = 0.32, p = 0.99 Cohen's d as compared with G3: G1 Post-tx: 0.36 G2 Post-tx: 0.62 G1 3 month: 0.36 G2 3 month: 0.65 G1 6 month: 0.31 G2 6 month: 0.55 | NR |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Connor et al., 1999[170](#_ENREF_170)  Meltzer-Brody et al., 2000[171](#_ENREF_171) | G1: Fluoxetine  10 to 60 mg/day  G2: Placebo | SIP  Week 12 difference (Baseline - Endpoint) (95% CI)  G1 vs. G2 difference: 10.3 (3.7 to 16.9), p<0.005  According to Meltzer-Brody paper, effect was significant for all 4 cluster scores (p<0.02) (intrusion, avoidance, numbing, hyperarousal)  Duke Global Severity Rating for PTSD (Duke)  Week 12 difference (Baseline - Endpoint) (95% CI)  G1 vs. G2 Difference: 1.1 (0.6 to 1.6), p<0.0001 | DTS  Week 12 difference (Baseline - Endpoint) (95% CI)  G1 vs. G2 Difference: 27.4 (11.2 to 43.5), p<0.005  According to Meltzer-Brody paper, effect was significant (p<0.02) for all 4 cluster scores (intrusion, avoidance, numbing, hyperarousal) | NR  NR |
| Cook et al., 2010[156](#_ENREF_156) | G1: CBT, exposure-based therapy  G2: Psychoeducation | CAPS Mean (SD) G1 Pre-tx: 81.34 (14.00) G1 Post-tx: 74.04 (20.36)  G2 Pre-tx: 79.48 (15.27) G2 Post-tx:74.85 (19.52)  p<0.001 (treatment effect, Wald) | PTSD Military Checklist  Mean (SD)  G1 Pre-tx: 62.73 (10.18)  G1 1 mth:58.83 (13.56)  G1 3 mth FU: 60.13 (12.16)  G1 6 mth FU: 59.05 (11.78)  G2 Baseline:65.06 (9.48)  G2 1 mth:60.96 (11.43)  G2 3 mth FU:61.13 (12.00)  G2 6 mth FU: 59.64 (12.30)  Interactions, NS | NR  NR |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Cottraux, 2008[31](#_ENREF_31) | G1: CBT-mixed  (Exposure in imagination or in vivo and cognitive therapy)  G2: Supportive Control | NR | PCLS <44 (criteria for loss of PTSD diagnosis) (Post-tx):  G1: 33%  G2: 14%  Fisher's exact, p=0.12  PCLS <35 (Post-tx)  G1: 20%  G2: 7%  Fisher's exact, p=0.25  PCLS, mean change (SD):  Mean change in G1: -13.5 (13.2)  Mean change in G2: -6.3 (12.9)  Group Effect, p=0.044  Interaction, NS | NR  Proportion without PTSD at posttest:  G1+G2 > G3, chi-sq = 10.58, df = 2, p=0.01 |
| Davidson et al., 2001[68](#_ENREF_68) | G1: Sertraline  50 to 200 mg/day  G2: Placebo | CAPS-2  Change from Baseline to Endpoint (SD) G1: -33.0 (2.4) G2: -26.2 (2.3) p=0.04 (t-test) | IES  Change from Baseline to Endpoint (SD)  G1: -19.2 (1.5)  G2: -14.1 (1.5)  p=0.02 (t-test)  DTS  Change from Baseline to Endpoint (SD)  G1: -32.3 (2.8)  G2: -20.0 (2.7)  p=0.002 (t-test) | NR  NR |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Davidson et al., 2003[184](#_ENREF_184) | G1: Mirtazapine  15 to 45 mg/day  G2: Placebo | SIP  Mean (SD)  G1 Pre-tx:34.7 (7.0)  G1 Post-tx:17.4 (4.0)  G2 Pre-tx:38.4 (6.7)  G2 Post-tx:32.9 (12.7)  Between Tx effect size 1.06  p=0.04  Treatment effect F=5.0; p=.04)  SPRINT  Mean (SD)  G1 Pre-tx:21.7 (6.0)  G1 Post-tx:12.4 (8.8)  G2 Pre-tx:25.0 (4.2)  G2 Post-tx: 19.4 (8.2)  Between Tx effect size 0.49  p=NS  Treatment effect, F=1.7; p=.20 | DTS  Mean (SD)  G1 Pre-tx: 74.8 (36.5)  G1 Post-tx: 54.1 (40.0)  Change: 20.7  G2 Pre-tx: 93.8 (29.4)  G2 Post-tx: 82.6 (27.7)  Change: 11.2  Treatment effect, p=0.20 | NR  NR |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Davidson et al., 2006[69](#_ENREF_69) | G1: Venlafaxine  75 to 300mg/day  G2: Sertraline  50 to 200mg/day  G3: Placebo | CAPS-SX17  Mean Within-group difference (95% CI): G1: -41.51 (-45.66 to -37.36)  G2: -39.44 (-43.67 to - 35.21) G3: -34.17 (-38.33 to -30.01)  Between group p-values based on pairwise comparisons from the analysis of covariance model using baseline adjusted values G1 vs. G3: 0.015 G2 vs. G3: 0.081 G1 vs. G2: 0.494 | DTS  Mean Within-group difference (95% CI):  G1: -42.86 (-47.56 to  -38.17)  G2: -38.92 (-43.69 to  -34.16)  G3: -34.59 (-39.27 to  -29.91)  Between group p-values based on pairwise comparisons from the analysis of covariance model using baseline adjusted values  G1 v G3: 0.015  G2 v G3: 0.203  G1 v G2: 0.248 | CAPS-SX17 total ≤ 20 Scores reported in figure  G1 vs. G3: p<0.05 at week 4 & 12 G1 vs. G2: p<0.01 at week 4, <0.05 at week 6 G1 vs. G3: p<0.001 at week 6  NR |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Davidson et al., 2006[73](#_ENREF_73) | G1: Venlafaxine  37.5 to 300 mg/day  G2: Placebo | CAPS-SX  Mean (SD) G1 Pre-tx: 81.0 (14.62) G1 Post-tx: 29.2 (26.09)  G2 Pre-tx: 82.9 (15.50) G2 Post-tx: 38.1 (29.11)  Between Group Mean Difference  -8.9, p=0.006 | NR | Remission Rates at 12 weeks (score ≤ 20 on CAPS-SX) G1: 42.9% (n=69/161) G2: 28.0% (n=47/168)  p=0.005  Remission Rates at 24 weeks (score ≤ 20 on CAPS-SX) G1: 50.9% (n=82/161) G2: 37.5% (n=63/168)  p=0.01  NR |
| Davidson et al., 2007[166](#_ENREF_166) | G1: Tiagabine  4 to16mg/day  G2: Placebo | CAPS  Change from baseline (SD)  G1: 30.7 (25.1) G2: 30.2 (26.3) p=0.85  DTS & TOP-8 NR, both NS | NR | G1: 16%  G2: 14%  p=0.88  NR |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Davis et al., 2008[164](#_ENREF_164) | G1: Divalproex  1000 to 3000 mg/day  G2: Placebo | CAPS  Mean(SD) G1 Pre-tx: 75.2 (19.1)  G1 Post-tx: 60.1 (24.1)  G2 Pre-tx: 77.3 (15.3) G2 Post-tx: 60.8 (26.6)  30% reduction in PTSD scores: G1: NR G2: NR Diff b/t groups, p>0.45  G1 vs. G2, diff over time, p=NS  TOP-8  Mean(SD)  G1 Pre-tx: 19.4 (5.3)  G1 Post-tx: 15.4 (6.6)  G2 Pre-tx: 19.7 (4.3)  G2 Post-tx: 15.8 (6.5)  G1 vs. G2, NS | DTS  Data Not Presented  G1 vs. G2, NS | NR  NR |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Ehlers et al., 2003[5](#_ENREF_5) | G1: CT  G2: Self-help booklet based on principles of CBT  G3: Repeated assessments | CAPS Frequency  Mean (SD)  G1 Pre-tx: 31.7 (9.5)  G1 3 mth FU: 11.2(10.3)  G1 9 mth FU: 10.2 (9.9)  G2 Pre-tx: 32.6 (8.6)  G2 3 mth FU: 22.9 (12.9)  G2 9 mth FU: 21.4 (11.4)  G3 Pre-tx: 32.8 (11.5)  G3 3 mth FU: 25.6 (12.9)  G3 9 mth FU: 21.1 (15.2)  3 mth FU  Overall: p<0.001  G1 vs. G2, p<0.001  G1 vs. G3, p<0.001  9 mth FU  Overall: p<0.001  G1 vs. G2: p<0.001  G1 vs. G3: p=0.001  CAPS Intensity  Mean (SD)  G1 Pre-tx: 26.7 (7.4) G1 3 mth FU: 10.2 (9.4)  G1 9 mth FU: 9.7 (9.5)  G2 Pre-tx: 26.7 (7.4)  G2 3 mth FU: 19.6 (9.0)  18.6 (10.1)  G2 9 mth FU: G3: 22.4 (11.9) | PDS Frequency  Mean (SD)  G1 Pre-tx: 30.2 (7.9)  G1 3 mth FU: 8.3 (9.8)  G1 9 mth FU: 8.7 (8.1)  G2 Pre-tx: 30.9 (7.5)  G2 3 mth FU: 19.9 (7.8)  G2 9 mth FU: 20.0 (7.8)  G3 Pre-tx: 31.1 (7.5)  G3 3 mth FU: 22.6 (11.6)  G3 9 mth FU: 19.4 (12.5)  3 mth FU  Overall: p<0.001  G1 vs. G2, p<0.001  G1 vs. G3, p<0.001  9 mth FU  Overall: p <0.001  G1 vs. G2, p<0.001  G1 vs. G3, p<0.001  PDS Distress  Mean (SD)  G1 Pre-tx: 31.6 (9.1)  G1 3mth FU: 7.1 (10.3)  G1 9 mth FU: 7.3 (8.6)  G2 Pre-tx: 32.0 (7.2)  G2 3 mth FU: 20.3 (8.2)  G2 9 mth FU: 19.0 (8.8) | NR  NR |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Ehlers et al., 2003[5](#_ENREF_5)  (continued) |  | G3 Pre-tx: 25.9 (10.4)  G3 3 mth FU: 22.4 (11.9)  G3 9 mth FU: 17.0 (13.8)  3 mth FU  Overall: p <0.001  G1 vs.G2: p<0.001  G1 vs. G3: p<0.001  9 mth FU  Overall, p=0.002  G1 vs.G2, p=0.001  G1 vs. G3, p=0.004 | G3 Pre-tx: 31.4 (8.4)  G3 3 mth FU: 22.3 (12.2)  G3 9 mth FU: 20.0 (14.1)  3mth FU  Overall: p<0.001  G1 vs. G2: p<0.001  G1 vs. G3: p<0.001  9 mth FU  Overall: p <0.001  G1 vs. G2, <0.001  G1 vs. G3, <0.001 |  |
| Ehlers et al., 2005[8](#_ENREF_8) | G1: CBT-mixed  Cognitive therapy including restructuring and exposure  G2: WL | CAPS-Intensity  Mean (SD) G1 Pre-tx: 36.5 (9.4) G1 Post-tx: 13.7 (13.4) G1 Post-tx FU adjusted: 10.4 G1 6 mth FU: 15.5 (14.8)  G2 Pre-tx: 29.0 (8.5) G2 Post-tx: 30.9 (9.6) G2 Post-tx adjusted: 34.2  G1 vs. G2, p<0.005  Changes in G1, p<0.005  Changes in G2, NS  CAPS-Frequency  Mean (SD) G1 Pre-tx: 42.0 (8.5) G1 Post-tx: 16.0 (15.3) G1 Post-tx adjusted: 11.4 G1 6 mth FU: 16.0 (14.4) | PDS  Mean (SD)  G1 Pre-tx: 32.4 (6.5)  G1 Post-txt: 10.3 (8.9)  G1 6 mth FU: 12.4 (9.9)  G2 Pre-tx: 31.2 (6.3)  G2 Post-txt: 29.8 (8.4)  G1 vs. G2, p<0.0005  Changes in G1, p<0.0005  Changes in G1, NS | NR  NR |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Ehlers et al., 2005[8](#_ENREF_8)  (continued) |  | G2 Pre-tx: 31.6 (8.4) G2 Post-tx: 35.5 (11.4) G2 Post-tx adjusted: 40.2  G1 vs. G2, p<0.005  Changes in G1, p<0.005  Changes in G2, NS |  |  |
| Ehlers et al., 2014[9](#_ENREF_9) | G1: Intensive CT (standard CT delivered over a much shorter period)  G2: Standard CT  G3: Supportive Therapy  G4: WL | CAPS  Mean (SD)  G1 Pre-tx: 78.72 (19.80)  G1 Post-tx: 32.22 (27.20)  G1 Followup 1 (27 weeks): 35.56 (26.26)  G1 Followup 2 (40 weeks):35.33(35.11)  Within-group pre-post effect, d= 1.95  G2 Pre-tx: 70.60 (13.45)  G2 Post-tx: 26.97 (28.68)  G2 Followup 1 (27 weeks): 20.86 (25.23)  G2 Followup 2 (40 weeks): 20.96 (27.71)  Within-group pre-post effect, d = 1.95  G3 Pre-tx: 74.60 (15.39)  G3 Post-tx: 47.88 (31.77)  G3 Followup 1 (27 weeks):49.32(32.46)  G3 Followup 2 (40 weeks): 49.04 (38.01)  Within-group pre-post effect, d = 1.07 | PDS  Mean (SD)  G1 Pre-tx: 33.21 (7.66)  G1 6 weeks: 14.85(8.92)  G1 Post-tx:11.98 (9.60)  G1 Followup 1 (27 weeks): 13.91 (11.63)  G1 Followup 2 (40 weeks):13.03(13.99)  Within-group pre-post effect, d= 2.45  G2 Pre-tx: 32.44 (6.94)  G2 6 weeks: 16.33 (11.58)  G2 Post-tx: 9.39 (10.88)  G2 Followup 1 (27 weeks): 10.15 (11.86)  G2 Followup 2 (40 weeks): 9.63 (11.26)  Within-group pre-post effect, d = 2.53  G3 Pre-tx: 34.26 (7.40)  G3 6 weeks: 23.30 (12.90)  G3 Post-tx: 19.98 (13.67)  G3 Followup 1 (27 weeks):18.93(12.98)  G3 Followup 2 (40 weeks): 20.94 (15.40)  Within-group pre-post effect, d = 1.30  G4 Pre-tx: 32.46 (7.60)  G4 6 weeks: 31.92 (6.84)  G4 Post-tx: 29.24 (9.36)  Within-group pre-post effect, d = 0.38 | Total Remission (no symptoms according to CAPS), n (%)  G1 Post-tx:14 (46.7)  G2 Post-tx:16 (51.6)  G3 Post-tx:6 (20.0)  G4 Post-tx: 1 (3.3)  Greater remission in G1 and G2 vs. G3  X2 = 22.19, p<0.001  G1 Followup 1 (27 weeks):12 (40.0)  G2 Followup 1 (27 weeks):21 (67.7)  G3 Followup 1 (27 weeks):5 (16.7)  Greater remission in G1 and G2 vs. G3  X2 = 16.41, p<0.001  G1 Followup 2 (40 weeks):16 (53.3)  G2 Followup 2 (40 weeks):23 (74.2)  G3 Followup 2 (40 weeks):8 (26.7)  Greater remission in G1 and G2 vs. G3  X2 = 13.84, p<0.01  G1 NNT: 1.50 (95% 1.18 to 2.06)  G2 NNT: 1.41 (95% 1.14 to 1.87)  G3 NNT: 2.73 (95% 1.77 to 5.95) |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Ehlers et al., 2014[9](#_ENREF_9)  (continued) |  | G4 Pre-tx: 69.95 (14.17)  G4 Post-tx: 65.28 (20.64)  Within-group pre-post effect, d = 0.26  Comparison of Treatment with Waitlist  Treatment by time Interactions, F=21.50, df=3, 135.35, p<0.002  Between group effect sizes  Adjusted Difference (95% CI)  G1 vs. G4: -39.55 (26.60 to 52.51), p<0.001, d = 1.57  G2 vs. G4: -38.80 (26.19 to 51.40), p<0.001, d= 1.55  G1 vs. G3: -18.72(5.96 to 31.45), p <0.01, d=0.75  G2 vs G3: -17.96 (5.31 to 30.62), p<0.01, d = 0.72  Interaction between condition and Linear time effects: F=7.83, df=2, 154.13, p<0.001 | Comparison of Treatment with Waitlist  Treatment by time Interactions, F=21.16, df=3, 106.56, p<0.002  Between group effect sizes  Adjusted Difference (95% CI)  G1 vs. G4: 17.72 (12.54 to 22.90), p<0.001, d = 1.75  G2 vs. G4:19.84 (14.71 to 24.97), p<0.001, d= 1.96  G1 vs. G3: 7.37(2.19 to 12.55), p <0.01, d=0.73  G2 vs G3: 17.96 (5.31 to 30.62), p<0.01, d = 0.72  Interaction between condition and Linear time effects: F=4.42, df=2, 215.14, p = 0.01 | Loss of Diagnosis (CAPS, patient no longer met the minimum number of symptoms in each symptom cluster) required by DSM-IV,), n (%)  G1 Post-tx:22 (73.3)  G2 Post-tx:24 (77.4)  G3 Post-tx:13 (43.3)  G4 Post-tx: 2 (6.7)  Greater loss of diagnosis in G1 and G2 vs. G3  X2 = 38.92, p<0.001  G1 Followup 1 (27 weeks):22 (73.3)  G2 Followup 1 (27 weeks):23 (74.2)  G3 Followup 1 (27 weeks):11 (36.7)  Greater loss of diagnosis in G1 and G2 vs. G3  X2 = 11.70, p<0.01  G1 Followup 2 (40 weeks):20 (66.7)  G2 Followup 2 (40 weeks):23 (74.2)  G3 Followup 2 (40 weeks):12 (40.0)  Greater loss of diagnosis in G1 and G2 vs. G3  X2 = 8.18, p<0.05 |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Engel et al., 2015[26](#_ENREF_26) | G1: DESTRESS-PC, a nurse guided online CBT and stress inoculation training.  G2: Optimized Usual Care, usual primary care PTSD treatment augmented with low intensity care management, feedback to the primary care provider, and training of the clinic providers in management of PTSD. | NR | PCL  Mean (SD)  G1 Pre-tx: 58.00 (9.95)  G1 Post-tx (6 weeks, end of treatment): 50.72 (18.76)  G1 Post-tx (12 weeks post randomization): 43.80 (18.33)  G1 Post-tx (18 weeks post randomization): 44.58 (16.43)  G2 Pre-tx: 54.48 (11.23)  G2 Post-tx (6 weeks, end of treatment): 48.52 (13.97)  G2 Post-tx (12 weeks post randomization): 47.36 (17.45)  G2 Post-tx (18 weeks post randomization): 42.74 (14.42)  Treatment by time interaction, F(3, 186) = 3.72, p = 0.12  Largest treatment effect seen at 12 weeks post randomization (6 week followup), t(186)=2.44, p=.016 and diminishing by the 18-week post randomization (12 week followup) assessment (presented in figure)  Effect Sizes  6-week (end of treatment): 0.23  12-week (6 weeks posttreatment): 0.47  18-week (12 weeks posttreatment): 0.08 | NR  NR |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Fecteau et al., 1999[38](#_ENREF_38) | G1: CBT-mixed  (Coping skills, exposure-therapy, and cognitive restructuring)  G2: WL | CAPS-2  Mean (SD) G1 Pre-tx: 70.9 (16.2)  G1 Post-tx: 37.5 (30.4)  G2 Pre-tx: 77.3 (22.7)  G2 Post-tx: 74.6 (24.7)  Group effects, p<0.01 | IES-I  Mean (SD)  G1 Pre-tx: 20.4 (8.7)  G1 Post-tx: 8.3 (8.9)  G2 Pre-tx: 24.8 (8.0)  G2 Post-tx: 24.4 (8.4)  Group Effects, p<0.01  IES-A  Mean (SD)  G1 Pre-tx: 24.7 (8.2)  G1 Post-tx: 7.2 (11.4)  G2 Pre-tx: 26.5 (10.5)  G2 Post-tx: 24.4 (6.3)  Group Effects, p<0.001  Followup for G1 Only  IES  Mean (SD)  G1 Pre-tx: 46.1 (14.7)  G1 Post-tx: 15.5 (19.6)  G1 3 mth FU: 13.0 (14.9)  G1 6 mth FU: 8.3 (7.0)  3 mth change, p<0.001 (n = 10)  6 mth change, p<0.001 (n = 8) | NR  NR |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Foa et al., 1999[14](#_ENREF_14)  Zoellner et al., 1999[134](#_ENREF_134) | G1: CBT, exposure-based therapy (PE)  G2: CBT, coping skills therapy  SIT  G3: CBT-mixed  Combined treatment (PE and SIT)  G4: WL | PSS-I  Mean (SD)  G1 Pre-tx: 29.48 (9.94)  G1 Post-tx: 11.70 (7.32)  G1 3 mth FU: 11.84 (9.01)  G1 6 mth FU: 11.16 (7.38)  G1 12 mth FU: 10.69 (8.96)  G2 Pre-tx: 29.42 (8.69)  G2 Post-tx: 12.89 (8.96)  G2 3 mth FU: 15.06 (13.33)  G2 6 mth FU: 11.24 (11.86)  G2 12 mth FU: 12.64 (14.71)  G3 Pre-tx: 29.95 (6.97)  G3 Post-tx: 13.55 (9.35)  G3 3 mth FU:11.45 (9.03)  G3 6 mth FU: 13.17 (10.98)  G3 12 mth FU: 12.56 (12.25)  G4 Pre-tx 32.93 (5.89)  G4 Post-tx: 26.93 (8.47)  Main Effects, p<0.01  G1 vs. G4, p<0.001  G2 vs. G4, p<0.05  G3 vs. G4, p<0.05  G1 vs. G2, p=0.14  G1 vs. G3, p=0.11 | NR | NR  NR |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Foa et al., 2005[12](#_ENREF_12) | G1: CBT, exposure-based therapy(PE)  G2: CBT-mixed  (PE plus CR)  G3: WL | PSS-I  Mean (SD)  G1 Pre-tx: 34.0 (5.9)  G1 Post-tx: 17.9 (14.5)  G2 Pre-tx: 31.1 (8.1)  G2 Post-tx: 16.8 (13.2)  G3 Pre-tx: 33.3 (6.2)  G3 Post-tx: 26.8 (9.6)  Group X Time interaction, p<0.01  G1 vs. G3 t-test, p<0.001 | NR | NR  NR |
| Fonzo et al., 2017[137](#_ENREF_137)  Fonzo et al., 2017[21](#_ENREF_21) | G1: PE  G2: WL | CAPS  Mean (SD)  G1 Pre-tx: 66.33 (15.17)  G1 Post-tx: 29.60 (21.26)  G2 Pre-tx: 71.37 (14.99)  G2 Post-tx: 64.23 (21.77)  Group X Time interaction, p<0.001 | PTSD Checklist for DSM-IV-Civilian Version  Mean (SD)  G1 Pre-tx: 56.16 (10.61)  G1 Post-tx: 26.13 (7.08)  G2 Pre-tx: 57.36 (12.04)  G2 Post-tx: 49.00 (13.35)  Group X Time interaction, p<0.001 | Remission (CAPS <20)  G1:10  G2:0  Loss of PTSD Diagnosis  G1: 21  G2: 0 |
| Forbes et al., 2012[4](#_ENREF_4) | G1: CBT, cognitive processing therapy  G2: TAU | CAPS  Mean (SD)  G1 Pre-tx: 75.53 (16.35)  G1 Post-tx: 48.03 (27.89)  G1 3 month FU: 45.30 (28.15)  G2 Pre-tx: 64.55 (19.46)  G2 Post-tx: 57.73 (20.01)  G2 3 month FU: 52.55 (18.93)  Change over time  Post-tx, p=0.002  Post vs. 3 month FU, p=0.649 | PCL  Mean (SD)  G1 Pre-tx: 61.63 (11.50)  G1 Post-tx: 45.67 (16.66)  G1 FU: 41.13 (17.51)  G2 Pre-tx: 57.45 (12.55)  G2 Post-tx:53.84 (11.11)  G2 FU: 49.11 (11.00)  Change over time  Post-tx, p=0.007  FU, p=0.943 | Loss of PTSD diagnosis  G1:30  G2: 10 |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Ford et al., 2011[59](#_ENREF_59) | G1: TARGET  G2: PCT  G3: WL | CAPS  Mean (SD)  G1 Pre-tx: 62.3 (18.1)  G1 Post-tx:38.7 (25.6)  G2 Pre-tx: 61.9 (21.3)  G2 Post-tx: 39.7 (21.4)  G3 Pre-tx: 68.7 (17.0)  G3 Post-tx: 62.5 (23.3)  Group X Time Effect, p<0.001 | NR | Met Criteria for full remission at Posttreatment  G1: 21%  G2: 15%  G3: 0  G1 vs. G2, p=0.45  G1 vs, G3, p<0.001  G2 vs. G3, p=0.007  Met Criteria for full remission at 3 month FU  G1:29%  G2:19%  Met Criteria for full remission at 6 month FU  G1: 33%  G2: 24.5%  Approximately 60% in each group were in partial remission.  Lost of PTSD diagnosis  Baseline to Post-tx  G1:35%  G2: 29%  G3: 11% |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Ford et al., 20131[60](#_ENREF_60) | G1: TARGET  G2: SGT | CAPS  Mean (SD)  G1 Pre-tx: 65.3 (18.0)  G1 Post-tx: 50.0 (20.8)  G2 Pre-tx: 63.1 (21.7)  G2 Post-tx: 50.5 (24.3)  Treatment X Time Interaction at post-tx, F= 0.3, NS, d = 0.13 | NR | Full remission (no full PTSD or partial PTSD at post-tx)  G1: 4 (12%)  G2: 8 (23%)  Loss of PTSD Diagnosis (no longer meet criteria for full PTSD at post-tx)  G1: 17 (43%)  G2: 15 (44%) |
| Friedman et al., 2007[70](#_ENREF_70) | G1: Sertraline  25 to 200 mg/day  G2: Placebo | CAPS-2 Change at Endpoint (SE)  G1: -13.1(3.0)  G2: -15.4(3.1)  Between Group Differences, NS | IES  Change at Endpoint (SE)  G1: -8.7(1.8)  G2: -8.1(1.9)  Between Group Differences, NS  DTS  Change at Endpoint (SE)  G1: -11.4 (3.5)  G2: -10.5 (3.5)  Between Group Differences, NS  MISS-Civilian Trauma Version  Change at Endpoint (SE)  G1: -4.3 (1.7)  G2: -2.8 (1.7)  Between Group Differences, NS | NR  NR |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Galovski et al., 2012[6](#_ENREF_6) | G1: Modified CBT. Modifications include potential addition of stressor sessions and variable length of treatment.  G2: Delayed treatment symptom monitoring | CAPS  LSM (SE)  G1 Pre-tx: 74.45 (2.42)  G1 Post-tx: 26.96 (3.88)  Difference: -47.5  G2 Pre-tx: 77 (2.57)  G2 Post-tx: 61.18 (3.98)  Difference: -15.8  (Hedge's g = 1.35)  G1 vs. G2 Difference, -31.7, p <0.001 | PDS  LSM (SD)  G1 Pre-tx: 31.88 (1.25)  G1 Post-tx: 11.63 (2.01)  Difference: -20.3  G2 Pre-tx: 35.28 (1.24)  G2 Post-tx: 26.81 (2.07)  Difference: -8.5  (Hedge's g = .86)  G1 vs. G2 Difference,-12.7, p <0.001 | NR  NR |
| Gamito et al., 2010[141](#_ENREF_141) | G1: VRET  G2: CBT, exposure-based therapy (Imaginal exposure)  G3: WL | CAPS G1 Percentage variation: -8 G2 Percentage variation: -1 G3 Percentage variation: -6  Effects, NS | IES-R  G1 Percentage variation: -1  G2 Percentage variation: 1  G3 Percentage variation: 7 | NR  NR |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Gersons et al., 2000[51](#_ENREF_51) | G1: Eclectic psychotherapy (Brief Eclectic Psychotherapy)  G2: WL | NR | NR | Proportions by Treatment (%, p values)  No PTSD Posttest G1: 91% G2: 50% p<0.01  3-month Followup G1: 96% G2: 35% p<0.01  NR |
| Haller et al., 2016[145](#_ENREF_145) | G1: Group ICBT for depression and SUD plus CPT-M (trauma-focused CPT modified to include substance use prevention) (individual)  G2: Group ICBT for depression and SUD plus ICBT for depression and SUD (individual) | NR | PCL  Mean (SD)  G1 Pre-tx: 51.46 (15.48)  G1 Post-tx: 49.62 (14.04)  G1 Post-tx (1 year followup): 48.33 (17.14)  G2 Pre-tx: 49.88 (16.06)  G2 Post-tx: 46.69 (15.74)  G2 Post-tx (1 year followup): 39.47 (16.46)  Scores were lower at the one year followup for participants in G2 compared to G1, F(1,71)= 5.58, p =.023. (based on only those participants who were assessed)  Trajectory models that account for missing values did not indicate significant differences between groups over time. | NR  NR |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Hamner et al., 2003[83](#_ENREF_83) | G1: Risperidone  1 to 6 mg/day  G2: Placebo | CAPS  Mean (SD) G1 Pre-tx: 90.3 (23.0) G1 Post-tx: 81.3 (24.3)  G2 Pre-tx: 89.1 (12.2) G2 Post-tx: 79.0 (21.0)  Between-treatment changes, NS | NR | NR  NR |
| Harned et al., 2014[144](#_ENREF_144) | G1: DBT plus DBT PE  G2: DBT | PSS-I  Mean (SD)  G1 Pre-tx: 32.8 (8.0)  G1 Post-tx: 13.6 (13.2)  G1 3 month followup: 16.7 (14.1)  G2 Pre-tx: 30.1 (9.6)  G2 Post-tx: 13.8 (9.3)  G2 3 month followup: 18.4 (7.7)  Between Group Effect size, Post: 0.0, followup: 0.1  Treatment X time Interaction, F = 0.3 (3, 42), NS | NR | Loss of Diagnosis: Post-tx (ITT) (Defined as no longer meeting DSM-IV criteria for PTSD)  G1: 58.3%  G2:33.3%  Remission at 3 month followup  G1: 50%  G2: 0 |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Hien et al., 2004[57](#_ENREF_57) | G1: Seeking Safety  G2: Relapse prevention condition  (only substance abuse)  G3: UC (Non-randomized Standard community Care) | CAPS Frequency and Intensity Mean (SD) G1 Pre-tx: 72.17 (19.70)  G1 Post-tx: 57.15 (22.33)  G1 6 mth FU: 59.85 (21.12) G1 9 mth FU: 55.34 (20.85)  G2 Pre-tx: 70.38 (16.84)  G2 Post-tx: 51.21 (25.21)  G2 6 mth FU: 52.65 (24.08) G2 9 mth FU: 47.82 (27.73)  G3 Pre-tx: 73.88 (19.16)  G3 Post-tx:68.00 (24.20)  G3 6 mth FU:64.79 (23.81) G3 9 mth FU: 66.00 (23.99)  CAPS Global Severity Mean (SD) G1 Pre-tx: 2.73 (0.63)  G1 Post-tx: 2.14 (1.53)  G1 6 mth FU:  G1 9 mth FU: 1.79 (0.63)  G2 Pre-tx: 2.41 (0.70)  G2 Post-tx:1.75 (0.79)  G2 6 mth FU: 1.62 (0.65) G2 9 mth FU: 1.40 (1.12)  G3 Pre-tx: 2.82 (1.16)  G3 Post-tx: 2.43 (1.09)  G3 6 mth FU: 2.35 (0.70) G3 9 mth FU: 2.14 (1.07)  Significance NR for CAPS | IES-R  Mean (SD)  G1 Pre-tx: 47.49 (14.50)  G1 Post-tx: 33.57 (14.92)  G1 6 mth FU: 39.12 (17.23)  G1 9 mth FU: 35.11 (16.82)  G2 Pre-tx: 46.12 (10.57)  G2 Post-tx: 28.90 (19.94)  G2 6 mth FU: 36.38 (20.16)  G2 9 mth FU: 29.67 (18.84)  G3 Pre-tx: 51.52 (12.76)  G3 Post-tx: 40.64 (20.43)  G3 6 mth FU: 40.06 (17.62)  G3 9 mth FU: 47.57 (13.21) | NR  NR |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Hien et al., 2009[157](#_ENREF_157)  Hien et al., 2012[158](#_ENREF_158) | G1: Seeking Safety  G2: Psychoeducation | CAPS, ITT Analysis Data  Mean (SD) G1 Pre-tx: 61.6 (19.4)  G1 Post-tx: 31.7 (23.4)  G1 Average of FU: 24.3 (22.1)  G2 Pre-tx: 64.2 (19.4) G2 Post-tx.: 32.7 (23.4) G2 Average of FU: 27.1 (23.4)  Post-tx  G1 vs. G2, p<0.001 | PSS-SR, ITT Analysis Data  Mean (SD)  G1 Pre-tx: 45.4 (15.3)  G1 Post-tx: 32.7 (13.9)  G1 Average Over FU: 30.0 (13.0)  G2 Pre-tx: 45.6 (15.3)  G2 Post-tx.: 33.8 (15.1)  G2 Average Over FU: 32.0 (15.0)  Post-tx  G1 vs. G2, p=0.59  12-mth FU (Average Over)  G1 vs. G2, p=0.97 | NR  NR |
| Hinton et al., 2005[34](#_ENREF_34) | G1: CBT-mixed  (Information on PTSD and Panic Disorder, relaxation techniques, culturally appropriate visualization, cognitive restructuring, exposure to anxiety-related sensations and trauma related memories, emotional-processing protocol, and cognitive flexibility)  G2: WL | CAPS Mean (SD) G1 Pre-tx: 74.85 (14.67) G1 2nd Assessment: 39.25 (19.92)  G1 3rd Assessment: 41.30 (13.95)  G1 FU Assessment: 44.56 (14.58)  G2 Pre-tx: 75.91 (11.5) G2 2nd Assessment: 73.05 99.43)  G2 3rd Assessment: 45.05 (8.72)  G2 FU Assessment: 43.56 (10.22)  Group Diffferences at 2nd Assessment, p<0.001  Group Differences at 1st, 3rd, & 4th assessments, NS | NR | NR  Percentage who no longer met PTSD criteria at assessment 2  G1: 60% (n= 12)  G2: 0%  p<0.001 |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Hinton et al., 2009[151](#_ENREF_151) | G1: CBT-Mixed  (Information on PTSD and Panic Disorder, muscle relaxation, guided imagery, mindfulness training, yoga-like stretching, cognitive restructuring, various exercises to teach emotional distancing and switching, and interoceptive exposure)  G2: WL | CAPS  Mean (SD) G1 Pre-tx: 75.41 (13.47) G1 2nd Assessment: 46.83 (17.17) G1 3rd Assessment: 44.75 (14.85)  G2 Pre-tx: 77.25 (11.47) G2 2nd Assessment: 74.25 (9.43) G2 3rd Assessment: 45.83 (8.45)   Between group difference at 2nd assessment, p<0.01  Between group differences at 3rd assessment, NS | NR | NR  NR |
| Hinton et al., 2011[152](#_ENREF_152) | G1; CBT-mixed  Culturally Adapted CBT (coping skills, cognitive "modification", mentions exposure)  G2: Applied Muscle Relaxation | NR | PTSD Checklist Mean (SD)  G1 Pre-tx: 69.8 (6.5) G1 Post-tx: 39.1 (15.1)  G1 FU: 36.4 (12.7)  G2 Pre-tx: 71.1 (7.9)  G2 Post-tx: 61.6 (13.2)  G2 FU: 58.9 (14.7)  Post-tx  G1 vs. G2, p<0.05 (t-test)  FU  G1 vs. G2, p<0.05 (t-test) | NR  NR |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Hogberg et al., 2007[48](#_ENREF_48) | G1; EMDR  G2: WL | NR | IES  Mean (SD)  Pre-tx  G1 Pre-tx: 39.3 (17.2)  G1 Post-tx: 23.2 (17.4)  G2 Pre-tx: 39.1 (12.6)  G2 Post-tx: 34 (16.2)  Within-group effect over time:  G1: p<0.05  G2: p<0.05  Between group differences, NS | NR  6 EMDR patients retained PTSD diagnosis, but denominator not given  G1:67% (8 of 12)  G2: 11% (1 of 11)  p=0.02 |
| Hollifield et al., 2007[32](#_ENREF_32) | G1: Acupuncture  G2: CBT-mixed  (Cognitive restructuring, behavior activation, and coping skills)  G3: WL | NR | PSS-SR  Mean (SD)  G1 Pre-tx: 31.33 (10.10)  G1 Post-tx: 15.65 (13.95)  G1 3 mth FU: 15.42 (12.54)  G2 Pre-tx: 32.52 (6.63)  G2 Post-tx: 20.02 (10.56)  G2 3 mth FU: 16.68 (12.20)  G3 Pre-tx: 30.79 (9.54)  G3 Post-tx: 27.92 (12.33)  G3 3 mth FU: 27.92 (12.33)  RMANOVA  G1 vs. G2, p=0.29  G1 vs. G3, p<0.01  G2 vs. G3, p<0.01 | NR  PSS-SR <16 at end of tx:  G1: 68%  G2: 43%  G3: 19%  PSS-SR <16 at 3-months:  G1: 68%  G2: 62% |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Ivarsson et al., 2014[24](#_ENREF_24) | G1: Internet based CBT  G2: Delayed treatment attention control | NR | IES - (ITT)  Mean (SD)  G1 Pre-tx: 54.65 (13.16)  G1 Post-tx: 30.96 (16.06)  G2 Pre-tx: 54.87 (15.48)  G2 Post-tx:49.19 (18.09)  Differential average rates of changes between pre-and post treatment as a function of condition, -17.9 (95% CI, -25.2 to -10.6), t (58) = 4.9, P<0.001, d = 1.25 (95% CI, 0.65 to 1.80), favoring treatment  PDS - (ITT)  Mean (SD)  G1 Pre-tx: 31.90 (6.52)  G1 Post-tx: 17.32 (9.86)  G2 Pre-tx: 29.84 (8.77)  G2 Post-tx:25.04 (11.14)  Treatment by time interaction =, -9.6 (95% CI, -13.8 to -5.3), t (54) = 4.5, P<0.001, d = 1.24 (95% CI, 0.64 to 1.81), favoring treatment | Remission: NR  Loss of Diagnosis (no longer met criteria for PTSD based on CAPS):  G1:81.5% (22)  G2: 38.9 (14)  Est = -1.55, SE = 0.62, p = 0.01, OR = 0.12, (95% CI, 0.06 to 0.71)  Improvement based on CGI  G1:63% (17)  G2:13.8% (4)  Est = 2.36, SE = 0.67, p = 0.001, OR = 10.63, (95% CI, 2.86 to 39.5) |
| Johnson et al., 2011[29](#_ENREF_29) | G1: CBT-mixed  (Psychoeducation and CBT restructuring)  G2: UC | CAPS  Mean (SD) G1 Pre-tx: 53.34 (24.29)  G1 Post-tx: 24.76 (18.47)  G1 3 mth FU: 21.15 (24.79)  G1 6 mth FU: 18.62 (18.84)  G2 Pre-tx: 62.69 (25.38)  G2 Post-tx: 42.38 (29.33)  G2 3 mth FU: 31.27 (22.01)  G2 6 mth FU: 26.56 (25.83)   Time effect, *p<*0 .0001  Treatment effect, p>0.05 | NR | NR  NR |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Kearney et al., 2013[159](#_ENREF_159) | G1: MBSR+TAU G2: TAU (VHA health system) | NA | PCL  Mean (SD)  G1 Pre-tx: 59.88 (11)  G1 Post-tx: 52.45 (13)  G1 4 month followup: 54.43 (15)  G2 Pre-tx: 62.91 (11) G2 Post-tx: 58.5 (11) G2 4 Month followup: 60.16 (13)  Post-tx, Between group: d = -.51 (95%, CI, -1.12 to 0.11) 4 month followup: d = -.42 (95%, CI, -1.03 to 0.2)  Clinically meaningful change (>=10 points) at PostTx: Mindfulness: 8 (36.4%) TAU: 5 (25%) Clinically meaningful change (>=10 points) at 4months: Mindfulness: 9 (39.1%) TAU: 5 (26.3%) | NR  NR |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Krakow et al., 2001[52](#_ENREF_52) | G1: IRT  G2: WL | CAPS  Mean (SD)  G1 Pre-tx: 81.88 (16.96) G1 Post-tx: 49.58 (23.96) Change: 32.3 (21.40)  G1 Pre-tx: 79.62 (24.37) G2 Post-tx: 68.37 (27.26) Change: 11.25 (21.65)  G1 vs. G2, p<0.001  PSS  Mean (SD)  G1 Pre-tx: 28.29 (10.37)  G1 Post-tx: 17.19 (10.39)  Change: 11.1 (11.06)  G1 Pre-tx: 28.48 (11.73)  G2 Post-tx: 25.26 (11.78)  Change: 3.22 (9.02)  G1 vs. G2, p<0.001 | NR | NR  NR |
| Krystal et al., 2011[85](#_ENREF_85) | G1; Risperidone  1 to 4 mg/day  G2: Placebo | CAPS  Mean Difference (95 % CI)  2.73 (-0.74 to 6.20)  p=0.12 | NR | % of veterans remitted based on CAPS at 24 weeks ╪ G1: 4.9  G2: 4.0  % of veterans with mild symptoms/ subdiagnostic based on CAPS at 24 weeks ╪  G1: 14.6  G2: 6.5 |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Kubany et al., 2003[35](#_ENREF_35) | G1: CBT, cognitive restructuring  G2: WL | CAPS  Mean (SD)  G1 Pre-tx: 80.9 (20.7)  G1 Post-tx: 10.1 (19.3)  G1 3 mth FU: 7.9 (9.3)  G2 Pre-tx: 79.1 (22.1)  G2 Post-tx: 76.1 (25.2)  G2 Post-therapy: 11.6 (13.6)  G2 3 mth FU: 12.4 (13.8)    G1 Post-tx change, p<0.05  G2 Post-tx change, NS  G1 3 mth change, NS  G2 Post-therapy, p<0.05  G2 3 mth change, NS | NR | NR  No longer met diagnostic criteria for PTSD Based on CAPS  G1: 94.0%  G1: 0.0% |
| Kubany et al., 2004[28](#_ENREF_28) | G1: CBT-Mixed (Cognitive Trauma Therapy-Battered Women)  G2: WL | CAPS (ITT Sample)  Mean (SD)  G1 Pre-tx:74.4 (19.9)  G1 Post-tx: 33.3 (32.8)  G2 Pre-tx: 78.0 (20.5)  G2 Post-tx: 74.1 (21.9)  Between group significance, NR | NR | NR  Lost of PTSD diagnosis based on completers  G1: 91%  G2: NR |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Langkaas et al., 2017[142](#_ENREF_142) | G1: PE  G2: IRT | PSS-I  Mean (SD)  G1 Pre-tx: 34.9 (8.25)  G1 Post-tx: 19.7 (13.92)  G1 3 mth FU: 22.9 (15.74)  G2 Pre-tx: 33.2 (6.91)  G2 Post-tx: 21.9 (14.13)  G2 12 mth FU: 23.5 (15.13)  Treatment X Time Interaction, NS | NR | Recovered  G1 Post-tx: 48%  G2 Post-tx: 50%  G1 12 mth FU:39%  G2 12 mth FU:38%  Improved  G1 Post-tx: 13%  G2 Post-tx: 6%  G1 12 mth FU:13%  G2 12 mth FU: 9%  Loss of Diagnosis NR |
| Li et al., 2017[172](#_ENREF_172) | G1; Sertraline 135 mg  G2: Placebo | NR | IES-R  Change at endpoint  G1: -24.3 (-32.1 to -14.3)  G2:-18.1 (-25.7 to -11.8)  Difference between groups: -6.4 to -2.6), p <0.01 | CGI-Severity  Change at endpoint  G1: -1.0 (-1.6 to -0.4)  G2:-0.6 (-1.3 to -0.2)  Difference between groups: -0.4 to -0.2), p <0.01  Symptom reduction  G1: 36 (100%)  G2:25 (75%)  Loss of PTSD diagnosis NR |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Lindauer et al., 2005[50](#_ENREF_50) | G1: Eclectic psychotherapy  Brief Eclectic Psychotherapy  G2: WL | SI-PTSD Reexperiencing Score  Mean (SD)  G1 Pre-tx: 3.4 (0.9)  G1 Post-tx: 1.2 (1.5)  G2 Pre-tx: 3.9 (0.8)  G2 Post-tx: 3.1 (1.8)  G1 vs. G2, p<0.05  SI-PTSD Avoidance Score  Mean (SD)  G1 Pre-tx: 3.9 (1.1.)  G1 Post-tx: 1.6 (2.2)  G2 Pre-tx: 3.5 (0.7)  G2 Post-tx: 3.2 (1.7)  G1 vs. G2, NS  SI-PTSD Hyperarousal  Mean (SD)  G1 Pre-tx: 3.8 (0.9)  G2 Post-tx: 1.3 (1.8)  G2 Pre-tx: 3.8 (1.0)  G2 Post-tx: 2.7 (1.5)  G1 vs. G2, p<0.05 | NR | NR  SI-PTSD scale used to diagnose PTSD, % improved at Post-tx  G1: 83.3%  G2: 25%  p<0.05 |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Litz et al., 2007[33](#_ENREF_33) | G1: CBT-mixed  (Stress management skills, in vivo exposure, and relapse prevention)  G2: Internet-delivered supportive counseling | PSS-I  Mean (SD) (Completer Group)  G1 Pre-tx: 26.71 (9.02)  G1 Post-tx: 14.86 (13.35)  G1 3 mth FU: 13.20 (8.63)  G1 6 mth FU: 8.67 (7.98)  G2 Pre-tx: 29.16 (9.93)  G2 Post-tx: 20.00 (11.50)  G2 3 mth FU: 13.96 (8.63)  G2 6 mth FU: 17.50 (10.40)  ITT Analysis  Post-tx  Time effect, p<0.001  3 mth FU  G1 v.s G2, NS  Completer Analysis  3 mth FU  G1 vs. G2, NS  6 mth FU  Group Effect, p =0.06 |  | NR  % no longer meeting criteria for PTSD based on PSS-I <6  ITT Analysis  Post-tx:  G1:25%  G2: 5%  Likelihood ratio=3.89, p<0.05  3-mth F/U, p=NR  6 mth F/U  G1: 25%  G2: 3%  Likelihood ratio=8.35, p<0.01 |
| Maguen et al., 2017[25](#_ENREF_25) | G1: CBT, Impact of Killing (IOK)  G2: WL | NR | PCL  Mean (SD)  G1 Pre-tx: 48.6 (14.5)  G1 Post-tx: 41.3 (11.2)  Mean change: -7.33 (-14.71 to -0.05), t-test p = 0.0512  G2 Pre-tx: 52.9 (11.3)  G2 Post-tx: 50.7 (10.6)  Mean change: -2.13 (-5.97 to -1.71), t-test p = 0.2534  Between-group difference: -7.27 (-13.89 to -0.64), t-test p=0.033 | NR  NR |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Markowitz et al., 2015[132](#_ENREF_132)  Markowitz et al., 2016[261](#_ENREF_261) | G1: PE  G2: IPT  G3: RT | CAPS  Mean (SD)  G1 Pre-tx: 72.1 (18.2)  G1 Post-tx: 37.5 (28.8)  Change at Post-tx: 31.6, Effect size: 1.88  G2 Pre-tx: 68.9 (16.2)  G2 Post-tx: 39.8 (24.3)  Change at Post-tx: 28.6, Effect size: 1.69  G3 Pre-tx: 68.9 (16.4)  G3 Post-tx: 46.5 (31.0)  Change at Post-tx: 22.3, Effect size: 1.32  Treatment X Time Interaction at post-tx, X2= 1.07, p = 0.343  G1 vs. G3 Difference: -14.93, p = 0.010, Effect Size: -0.88  G2 vs. G3 Difference: -9.47, p = 0.097, Effect Size: -0.56  G2 vs. G1 Difference: 5.46, p = 0.323, Effect Size: 0.32 | Post Stress Scale  Mean (SD)  G1 Pre-tx: 77.7 (22.3)  G1 Post-tx: 34.1 (26.4)  Change at Post-tx: 36.1, Effect size: 1.81  G2 Pre-tx: 74.3 (20.2)  G2 Post-tx: 41.7 (26.1)  Change at Post-tx: 32.1, Effect size: 1.61  G3 Pre-tx: 83.2 (15.3)  G3 Post-tx: 64.7 (27.4)  Change at Post-tx: 14.1, Effect size: 0.71  Treatment X Time Interaction at post-tx, X2= 4.67, p = 0.010  G1 vs. G3 Difference: -30.75, p < 0.001, Effect Size: -1.55  G2 vs. G3 Difference: -18.22, p = 0.008, Effect Size: -0.92  G2 vs. G1 Difference: 12.54, p = 0.053, Effect Size: 0.63 | Remission (CAPS score <20)  G1: 26%  G2: 23%  G3: 22 %  NR |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Marks et al., 1998[122](#_ENREF_122)  Lovell et al., 2001[123](#_ENREF_123) | G1: CBT, exposure-based therapy(PE)  G2: CBT, cognitive restructuring  G3: CBT-mixed  Exposure (Combined with CR)  G4: Relaxation | Marks et al., 1998[122](#_ENREF_122)  CAPS-2, Mean Change Score at Post-tx (95% CI) G1: 30 (19 to 42)  G2: 36 (26 to 45) G3: 38 (26 to 50) G4: 14 (4 to 25)  Additional results presented in graphs  CAPS  Mean change in G1 + G2 + G3 vs. G4  Post, p=0.005  1 mth FU, p=0.01  3 mth FU, p=0.005  Lovell et al., 2001[123](#_ENREF_123)  CAPS, Re-experiencing subscale  Mean (SD)  G1 Pre-tx: 13.3 (3.9)  G1 Post-tx: 6.8 (7.5)  G2 Pre-tx: 14.9 (5.0)  G2 Post-tx: 7.8 (4.9)  G3 Pre-tx: 15.1 (6.4)  G3 Post-tx: 6.8 (7.2)  G4 Pre-tx: 11.6 (6.1)  G4 Post-tx: 9.7 (7.4)  Post-tx  G1 + G2 +G3 vs. G4, p<0.02  Followups  G1 + G2 +G3 vs. G4, NS | IES (first 11 weeks)  Mean Change Score (95% CI)  G1: 28 (19 to 37)  G2: 25 (15 to 34)  G3: 35 (24 to 49)  G4: 13 (5 to 19)  Additional results presented in graphs  IES  Mean change in G1 + G2 + G3 vs. G4  Post, p=0.008  1 mth FU, p=0.08  3 mth FU, p=0.05 | NR  PTSD Criteria not meet by CAPS  G1: 75%  G2: 65%  G3: 63%  G4: 55% |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Marks et al., 1998[122](#_ENREF_122)  Lovell et al., 2001[123](#_ENREF_123)cont’d |  | CAPS, Advoidance/numbing subscale  Mean (SD)  G1 Pre-tx: 23.4 (8.3)  G1 Post-tx: 11.5 (13.1)  G2 Pre-tx: 30.7 (7.6)  G2 Post-tx: 15.2 (11.0)  G3 Pre-tx: 29.8 (9.3)  G3 Post-tx: 11.9 (11.9)  G4 Pre-tx: 23.0 (9.1)  G4 Post-tx: 17.1 (8.9)  Post-tx  G1 + G2 +G3 vs. G4, p<0.004  1 month FU  G1 + G2 +G3 vs. G4, p<0.02  3 month FU  G1 + G2 +G3 vs. G4, p<0.01  CAPS, Increased arousal subscale  Mean (SD)  G1 Pre-tx: 25.2 (8.5)  G1 Post-tx: 13.2 (11.1)  G2 Pre-tx: 29.1 (8.8)  G2 Post-tx: 16.5 (10.0)  G3 Pre-tx: 28.6 (7.7)  G3 Post-tx: 16.6 (11.7) |  |  |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Marks et al., 1998[122](#_ENREF_122)  Lovell et al., 2001[123](#_ENREF_123)cont’d |  | G4 Pre-tx: 23.7 (7.6)  G4 Post-tx: 17.0 (10.5)  Post-tx  G1 + G2 +G3 vs. G4, NS |  |  |
| Marks et al., 1998[122](#_ENREF_122)  Lovell et al., 2001[123](#_ENREF_123)cont’d |  | Followups  G1 + G2 +G3 vs. G4, NS  CAPS, Associated features subscale  Mean (SD)  G1 Pre-tx: 16.7 (9.0)  G1 Post-tx: 8.1 (9.7)  G2 Pre-tx: 22.6 (10.2)  G2 Post-tx: 10.3 (8.8)  G3 Pre-tx: 20.8 (10.8)  G3 Post-tx: 11.0 (11.0)  G4 Pre-tx: 15.2 (8.0)  G4 Post-tx: 12.0 (11.0)  Post-tx  G1 + G2 +G3 vs. G4, p<0.04  Followups  G1 + G2 +G3 vs. G4, NS |  |  |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Marshall et al., 2001[64](#_ENREF_64) | G1: Paroxetine  20 mg/day  G2: Paroxetine  40 mg/day  G3: Placebo | CAPS-2 Adjusted Mean Differences (95% CI) G1 vs. G3 -14.3 (-19.7 to -8.8)  p<0.001  G2 vs. G3 -12.2 (-17.7 to -6.6)  p<0.001  TOP-8  Adjusted Mean Differences (95% CI)  G1 vs. G3  -3.4 (-5.1 to -1.8)  p<0.001  G2 vs. G3  -2.9 (-4.5 to -1.3)  p<0.001 | DTS  Adjusted Mean Differences (95% CI)  G1 vs. G3  -12.2 (-18.1 to -6.3)  p<0.001  G2 vs. G3  -10.9 (-16.9 to -4.9)  p<0.001 | NR  NR |
| Martenyi et al., 2002[61](#_ENREF_61)  Martenyi et al., 2006[173](#_ENREF_173) | G1: Fluoxetine  20 to 80 mg/day  G2: Placebo | CAPS Changes from Pre-tx to Post-tx Least Square Means (SD), p-value G1: -34.6 (28.1) G2: -26.8 (26.1) p=0.021  TOP-8  Changes from Pre-tx to Post-tx  Least Square Means, p-value  G1: -10.3  G2: -8.0  p=0.006 | DTS  Changes from Pre-tx to Post-tx  Least Square Means (SE), p-value  G1: -33.8 (2.25)  G2: -27.3 (3.66)  p=0.117 | NR  NR |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Martenyi et al., 2007[62](#_ENREF_62) | G1: Fluoxetine  20 mg/day  G2: Fluoxetine  40 mg/day  G3: Placebo | CAPS  Mean change from baseline (SD)  ITT Analysis G1: -42.9 (23.1) G2: -42.8 (27.9) G3: -36.6 (25.7)  Overall p-value= 0.15  TOP-8  Mean change from baseline (SE)  Completer analysis  G1: -10.59 (0.58)  G2: -10.25 (0.60)  G3: -10.59 (0.81)  Overall p-value= 0.907 | NR | NR  Loss of PTSD Diagnosis  G1: 40.5%  G2: 38.8%  G3: 37.5 |
| Maxwell et al., 2016[124](#_ENREF_124) | G1: MEST  G2: CPT | NR | MPSS-SR  Mean (SD)  G1 Pre-tx:63.50 (18.37)  G1 Post-tx:54.13 (24.87)  G1 3 mth FU: 33.5 (25.39)  G2 Pre-tx:49.00 (26.60)  G2 Post-tx:38.13 (15.06)  G2 3 mth FU: 25.13 (23.31)  Cohen’s d = .50 | NR  NR |
| McDonagh et al., 2005[39](#_ENREF_39) | G1: CBT-mixed (  Exposure and cognitive restructuring therapy)  G2: PCT  G3: WL | CAPS Mean (SD) G1 Pre-tx: 69.9 (16.8) G1 Post-tx: 53.1 (28.8)  G2 Pre-tx: 67.7 (14.6) G2 Post-tx: 47.2 (22.4)  G3 Pre-tx: 72.0 (17.6) G3 Post-tx: 65.5 (18.6)  Group X Time, p<0.10 | NR | NR  No longer met criteria for PTSD (CAPS)  G1: 27.6%  G2: 31.8%  G3: 17.4% |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| McGovern et al., 2015[27](#_ENREF_27) | G1: ICBT plus SC, manual-guided therapy focused on PTSD and  substance use.  G2: IAC plus SC, (focused exclusively on substance use and recovery) (arm not eligible)  G3: SC (intensive out-patient program services) | CAPS  Mean (SD)  G1 Pre-tx: 76.71 (18.13)  G1 Post-tx (6 month): 46.81(24.81)  G3 Pre-tx: 76.51 (20.83)  G3 Post-tx (6 month):52.60(26.46)  NS difference between G1 and G3  Parameter Estimate and CIs  G1 vs. G3, -4.95 (95% CI, -13.65 to 3.74)  Effect size  G1 vs. G3: -0.24 | NR | NR  NR |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Mills et al., 2012[20](#_ENREF_20) | G1: COPE, a modification of Concurrent Treatment of PTSD and Cocaine Dependence. (motivational enhancement, psychoeducation, in vivo exposure, imaginal exposure, and cognitive therapy) G2: TAU. | CAPS  Mean (95% CI) G1 Pre-tx: 91.13 (87.03 to, 95.23)  G1 Post-tx: 52.90 (43.72 to 62.06)  Mean difference: -38.24 (-47.93, -28.54), p < 0.001  G2 Pre-tx: 89.83 (84.70 to 94.06) G2 Post-tx: 67.23 (59.21 to 75.25)  Mean difference: -22.14 (-30.33 to -13.95), p < 0.001  Between group difference Pre-tx to FU: -16.09 (-29.00 to -3.19), p = 0.02  Treatment X Time Interaction: X2 = 5.38, p = 0.02 | NR | NR  NR |
| Monnelly et al., 2003[167](#_ENREF_167) | G1: Risperidone  0.5 to 2.0mg/day  G2: Placebo | NR | PCL-M  Median Change Scores  G1: -10.0  G2: -0.5  p=0.02 | NR  NR |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Monson et al., 2006[1](#_ENREF_1) | G1: CBT, CPT  G2: WL | CAPS Mean (SE) G1 Pre-tx: 76.73 (2.6) G1 Post-tx: 52.14 (3.9) G1 1 mth FU: 58.13 (4.5)  G2 Pre-tx: 79.10 (3.5) G2 Post-tx: 76.03 (3.7) G1 1 mth FU: 74.37 (4.3)  Group X Time, p<0.01 | NR | NR  Did Not Meet Diagnostic Criteria for PTSD at Post-treatment  G1: 40% (n=12)  G2: 3% (n=1)  p<0.001  Did Not Meet Diagnostic Criteria for PTSD at 1-month  G1: 30% (n= 9)  G2: 3% (n=1)  p=0.01 |
| Monson et al., 2012[22](#_ENREF_22) | G1: CBCT, manualized cognitive-behavioral conjoint therapy for PTSD delivered in a couple therapy format  G2: WL | CAPS  Mean (95% CI)  G1 Pre-tx: 68.87 (62.12 to 75.61)  G1 Post-tx: 33.45 (22.03 to 44.87)  Change: -35.42 (-47.84 to -23.00)  Effect size Hedge g: 1.82 (1.00 to 2.62)  G2 Pre-tx: 73.03 (66.29 to 79.76)  G2 Post-tx: 60.82 (49.87 to 71.78)  Change: -12.20 (-21.51 to -2.89)  Effect size Hedge g: 0.57 (0.12 to 1.00)  Change Difference Mean Between Groups: -23.21 (-37.87 to -8.55) | PTSD Checklist  Mean (95% CI)  G1 Pre-tx: 49.92 (45.12 to 54.71)  G1 Post-tx: 30.38 (22.81 to 37.96)  Change: -19.53 (-27.30 to -11.77)  Effect size Hedge g: 1.61 (0.83 to 2.37)  G2 Pre-tx: 57.89 (53.10 to 62.67)  G2 Post-tx: 46.80 (36.61 to 53.99)  Change: -11.09 (-18.34 to -3.85)  Effect size Hedge g: 0.71 (0.21 to 1.20)  Change Difference Mean Between Groups: -8.44  (-18.71 to -1.83)  Effect size Hedge g: 0.60 (-0.10 to 1.29) | NR  Loss of PTSD Diagnosis at posttreatment (not meeting DSM-IV-TR symptom criteria and a total score lower than  45 on the CAPS)  G1: 13 (81%)  G2: 4 (21%) |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Monson et al., 2012[22](#_ENREF_22) (continued) |  | Effect size Hedge g: 1.13 (0.40 to 1.85)  Treatment X Time Interaction, t (37, 5) = -3.09, p = 0.004 |  |  |
| Moradi et al., 2014[160](#_ENREF_160) | G1: MEmory Specificity Training (MEST)  G2: Control, no additional contact | NR | IES-R  Treatment X Time Interaction, F(2, 44) = 176.48, p < 0.001, η2 = 0.89 | NR  NR |
| Morath et al., 2014[55](#_ENREF_55) | G1: NET  G2: WL | CAPS  Mean (SD)  G1 Pre-tx: 92.41 (14.95)  G1 Post-tx: 58.65 (24.93)  G1 1 year post-tx:51.88 (24.52)  G2 Pre-tx: 76.88 (15.95)  G2 Post-tx: 74.59 (20.42)  Treatment X Time Interaction at post-tx, F (1, 32) = 16.90, p = 0.0003 | NR | NR  NR |
| Mueser et al., 2008[7](#_ENREF_7) | G1: CBT-mixed  (CBT for PTSD)  G2: UC | CAPS  Mean (SD) G1 Pre-tx: 74.46 (17.56) G1 Post-tx: 55.53 (27.92) G1 3 mth FU: 55.10 (25.96) G1 6 mth FU: 57.48 (25.34)  G2 Pre-tx: 76.15 (17.07) G2 Post-tx: 67.78 (26.84) G2 3 mth FU: 64.80 (28.25) G2 6 mth FU: 70.90 (24.15)  Group effect, p=0.005 | NR | NR  Loss of PTSD Diagnosis  CAPS Dx, n(%)  G1 Pre-tx: 54 (100.0)  G1 Post-tx: 21 (67.7)  G1 3 mth FU: 19 (63.3)  G1 6 mth FU: 24 (72.7)  G2 Pre-tx: 54 (100.0)  G2 Post-tx: 21 (77.8)  G2 3 mth: 27 (77.1)  G2 6 mth: 17 (85.0)  Group effect, p=0.63, |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Nacasch et al., 2011[15](#_ENREF_15) | G1: CBT, exposure-based therapy (Prolonged exposure therapy)  G2: TAU | PSS-I  Mean (SD)  G1 Pre-tx: 37.1 (3.8)  G1 Post-tx: 18.9 (9.1)  G1 FU: 16.3 (10.4)  G2 Pre-tx: 36.8 (6.2)  G2 Post-tx: 35.0 (8.9)  G2 FU: 35.4 (7.6)  Post-tx  Treatment X Time, p<0.001  12 month FU  Treatment X Time (Pre to FU), p<0.001  Treatment X Time (Post to FU), NS | NR | NR  NR |
| Neuner et al., 2004[161](#_ENREF_161) | G1: CBT, exposure-based therapy (NET)  G2: Supportive Counseling  G3: Psycho-education  About the nature and prevalence of PTSD | Composite International Diagnostic Interview-PTSD  Mean (SD)  G1 Pre-tx: 13.4 (2.1)  G1 1 year FU: 8.9 (2.7)  G2 Pre-tx: 13.9 (2.3)  G2 1 year FU: 12.6 (3.2)  G3 Pre-tx: 14.2 (2.9)  G3 1 year FU: 13.4 (3.3)  1 year Group X Time  G1 vs. G2, p=0.01  G1 vs. G3, p=0.01 | PDS  Mean (SD)  G1 Pre-tx: 25.2 (7.4)  G1 Post-tx: 19.1 (11.7)  G1 4 mth FU: 24.5 (7.8)  G1 1 year FU: 16.0 (5.1)  G2 Pre-tx: 22.0 (8.0)  G2 Post-tx:19.8 (10.9)  G2 4 mth FU: 22.8 (23.1)  G2 1 year FU: 23.1 (7.7)  G3 Pre-tx: 19.5 (8.0)  G3 Post-tx: 21.2 (9.4)  G4 Post-tx: 27.7 (6.6)  G3 1 year FU: 23.9 (7.0)  1 year Group X Time  G1 vs. G2, p=0.01  G1 vs. G3, p=0.01 | NR  Percentage of Patients Without a PTSD Diagnosis at 1 year followup  G1: 71.0%  G2: 21.0%  G3: 20.0% |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Neuner et al., 2008[54](#_ENREF_54) | G1: CBT, exposure based (NET)  G2: Flexible Trauma Counseling  G3: No-treatment monitoring group | PDS  Mean (SD)  G1 Pre-tx: 25.9 (13.2)  G1 Post-tx: 5.4 (6.6)  G1 6 mth FU: 6.1 (6.8)  G2 Pre-tx: 26.7 (12.5)  G2 Post-tx: 5.3 (5.7)  G2 6 mth FU: 5.0 (6.6)  G3 Pre-tx: 21.3 (10.6)  G3 Post-tx: NR  G3 6 mth FU: 10.1 (8.1)  G1 vs. G2 Comparisons  Group X Time at Post-tx, p=0.87  Treatment Groups vs. Control  Treatment X Time, p=0.01 | NR | NR  No longer fulfilled criteria for PTSD at 9 months.  G1: 69.85%  G2: 65.2%  G3: 36.8% |
| Neuner et al., 2010[53](#_ENREF_53) | G1: CBT, exposure based (NET)  G2: UC | PDS  Mean(SD)  G1 Pre-tx: 38.9 (6.4)  G1 Post-tx: 26.0 (9.2)  G2 Pre-tx: 36.9 (8.0)  G2 Post-tx: 34.1 (6.1)  Group X Time, p=0.01 | NR | NR  Loss of PTSD Diagnosis  G1: 6.25%  G2: 0% |
| Nijdam et al., 2012[154](#_ENREF_154) | G1: Eclectic psychotherapy  G2: EMDR | SI-PTSD  Mean Difference at 1st Post (95% CI)  10.80 (6.37 to 15.23)  p<0.001  Mean Difference at 2nd Post (95% CI)  2.41 (-2.10 to 6.92)  p=0.29 | NR |  |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Panahi et al., 2011[71](#_ENREF_71) | G1: Sertraline  50 to 200 mg/day  G2: Placebo | NR | NR |  |
| Petrakis et al., 2012[185](#_ENREF_185), [240](#_ENREF_240) | G1: Paroxetine (40 mg/day)+ Naltrexone (50 mg/day)  Participants who could not tolerate the highest dose were brought to lower doses.  G2: Paroxetine (40 mg/day) +Placebo  Participants who could not tolerate the highest dose were brought to lower doses.  G3: Desipramine (200 mg/day) + Naltrexone (50 mg/day)  Participants who could not tolerate the highest dose were brought to lower doses.  G4: Desipramine (200 mg/day + Placebo  Participants who could not tolerate the highest dose were brought to lower doses. | CAPS Mean(SE) G1 Pre-tx: 73.54 (5.007) G1 Post-tx: 40.024 (5.53)  G2 Pre-tx: 69.810 (5.166) G2 Post-tx: 36.591 (5.570)  G3 Pre-tx: 62.500 (5.047) G3 Post-tx: 26.751 (5.353)  G4 Pre-tx: 77.833 (4.832) G4 Post-tx: 41.392 (4.949)  Time effect, p<0.00  Group X Time, NS | NR | NR  NR |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Polusny et al., 2015[136](#_ENREF_136) | G1: 8 weekly group sessions and a daylong retreat. 1st session was an orientation that included rational and psychoeducation. 7 sessions of mindfulness therapy and 1 6.5 hour retreat.  G2: Group Sessions | CAPS  Mean (95% CI) G1 Pre-tx: 69.9 (51.0 to 61.5)  G1 Post-tx: 56.3 (51.0 to 61.5)  G1 2 month followup: 49.8 (44.3 to 55.3)  G2 Pre-tx: 62.5 (57.6 to 67.4)  G2 Post-tx: 51.7 (46.5 to 56.8)  G2 2 month followup: 50.6 (45.4 to 55.8)  Between group mean difference at post-tx: -2.35, p=0.37 Between group mean difference at 2 month followup: -7.89 p= 0.004  Treatment x time interaction at 2 months: F = 4.75, P =0.03  Clinically significant improvement:  G1 Post-tx: 33 (63.5%) G2 Post-tx: 28 (49.1%) G1 2 month followup: 30 (66.7%) G2 2 month followup: 30 (54.5%)  Between group mean difference at Post-tx: 14.3%, p = 0.13 Between group mean difference at 2 month followup: 42.1%, p=0.22 | PCL  Mean (95% CI) G1 Pre-tx: 63.6 (60.6 to 66.7)  G1 Post-tx: 55.7 (52.6 to 58.9)  G1 2 month followup: 55.4 (51.2 to 57.6)  G1 Pre-tx: 58.8 (55.7 to 61.8) G2 Post-tx: 55.8 (52.7 to 58.9) G2 2 month followup: 56.0 (52.9 to 59.0)  Between group mean difference at posttreatment: -4.95, p =0.002  Between group mean difference at 2 month followup: -6.44, t = 4.08, P <0.001  Group x time interaction at 2 months: F= 8.78, P=0.004  Clinically significant improvement:  G1 Post-tx: 19 (36.5%) G2 Post-tx: 13 (22.8%) G1 2 month followup: 23 (48.9%) G2 2 month followup: 16 (28.1%)  Between group mean difference at Post-tx: 13.7%, p =0.12 Between group mean difference at 2 month followup: 20.9%, p= 0.03 | Loss of CAPS diagnosis, n (%) G1 Post-tx: 22 (42.3%) G1 2 month followup: 24 (53.3%)  G2 Post-tx: 25 (43.9%)  G2 2 month followup: 26 (47.3%)  Post-tx, Between group mean difference: 1.6%, chi-sq = .03, p=0.87 2 month followup, Between group mean difference: 6%, chi-sq = .36, P=0.55  Remission NR |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Raskind et al., 2003[74](#_ENREF_74) | G1: Prazosin  2 to 10 mg/day  G2: Placebo | CAPS  G1 Pre-tx:79.1 (17.0) G1 Post-tx: 57.3 (32.3)  G2 Pre-tx: 83.6 (17.6) G2 Post-tx: 86.5 (30.0)  G1 vs. G2 Change, p<0.01 | NR | NR  NR |
| Raskind et al., 2007[75](#_ENREF_75) | G1: Prazosin  2 to 15 mg at bedtime  G2: Placebo | CAPS  Means (SD) G1 Pre-tx: 76.0 (22) G1 Post-tx: 63.0 (20.0)  G2 Pre-tx: 78.0 (18.0) G2 Post-tx: 71.0 (22.0)  G1 vs. G2 Change, NS | NR | NR  NR |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Raskind et al., 2013[76](#_ENREF_76) | G1: Prazosin 1 to 5 mg/day morning dose, 1 to 20mg/day bedtime dose  G2: Placebo | CAPS  Adjusted Means (95% CI)  G1 Pre-tx: 77.3 (69.1 to 85.5)  G1 Post-tx: 52.2 (43.8 to 60.5)  Mean Change: 25.1 (SE = 3.4)  G2 Pre-tx: 85.7 (78.0 to 93.3)  G2 Post-tx: 71.9 (63.9 to 79.8)  Mean Change: 13.8 (SE = 3.3)  Between Group Difference in Change from Baseline: 11.3 (2.0 to 20.7), t = 2.39, p = 0.02  Subgroup Analysis  Week-by-Treatment group-by-SSRI use Interaction for CAPS, p = 0.0007  Change in CAPS between baseline and week 15 (G1 only) Prazosin  Not Receiving SSRI: 30.1 point decrease (SE =3.8)  Receiving SSRI: 9.6 point decrease (SE=6.8) | NR | CGI  Adjusted Means (95% CI)  G1 Post-tx: 2.3 (1.8 to 2.7)  G2 Post-tx: 3.2 (2.8 to 3.6)  Between Group Difference in Change from Baseline: 0.9 (0.3 to 1.5), t = 3.13, p = 0.003  Treatment by SSRI use Interaction for CGI change NS  Responders (CGI change item markedly or moderately improved=scores of 1 or 2)  G1: 64% (44 to 79)  G2: 27% (14 to 45)  Difference in % responders, p<,0.001, OR = 4.8, (1.9 to 12.2)  Full Remission (CAPS <20)  G1: 3  G2: 0  Loss of PTSD diagnosis NR |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Reger et al., 2016[18](#_ENREF_18) | G1: VRE  G2: PE  G3: WL (minimum attention) | CAPS (week)  Mean (SD)  G1 Pre-tx: 80.44 (16.23)  G1 Post-tx: 57.07 (32.32)  G1 12 week: 56.64 (31.50)  G1 26 week: 53.50 (28.07)  G2 Pre-tx: 78.28 (16.35)  G2 Post-tx: 44.28 (33.73)  G2 12 week: 36.63 (31.80)  G2 26 week: 38.33 (28.49)  G3 Pre-tx: 78.89 (16.87)  G3 Post-tx: 68.06 (24.27)  G1 vs. G3 Post-tx Differences: -13.23 (95% CI, -23.22 to -3.23), p <0.005, ES = -0.81 (95% CI, -1.42 to -0.20)  G2 vs. G3 Post-tx Differences: -21.30 (95% CI, -31.60 to -12.19), p <0.001, ES = -1.33 (95% CI, -1.93 to -0.74)  G1 vs. G2 Post-tx Differences: 8.67 (95% CI, -1.86 to 19.20), p = 0.947, ES = 0.53 (95% CI, -0.11 to 1.17)  G1 vs. G2 12 week Differences: 14.50 (95% CI, 3.24 to 25.76), p = 0.994, ES = 0.88 (95% CI, 0.20 to 1.57)  G1 vs. G2 26 week Differences: 13.68 (95% CI, 1.45 to 25.91), p = 0.986, ES = 0.83 (95% CI, 0.09 to 1.58) | PCL-C  Mean (SD)  G1 Pre-tx: 61.85 (9.03)  G1 Post-tx: 45.57 (15.88)  G1 12 week: 46.96 (15.95)  G1 26 week: 42.88 (15.96)  G2 Pre-tx: 59.74 (9.09)  G2 Post-tx: 40.63 (18.57)  G2 12 week: 38.41 (17.98)  G2 26 week: 40.83 (18.56)  G3 Pre-tx: 60.30 (8.97)  G3 Post-tx: 53.89 (11.77)  G1 vs. G3 Post-tx Differences: -11.33 (95% CI, -16.18 to -6.48), p <0.001, ES = -1.26 (95% CI, -1.79 to -0.72)  G2 vs. G3 Post-tx Differences: -11.23 (95% CI, -15.93 to -6.54), p <0.001, ES = -1.25 (95% CI, -1.77 to -0.72)  G1 vs. G2 Post-tx Differences: -0.10 (95% CI, -5.18 to 4.98), p = 0.485, ES = -0.01 (95% CI, -0.57 to 0.55)  G1 vs. G2 12 week Differences: 2.86 (95% CI, -2.58 to 8.29), p = 0.849, ES = 0.32 (95% CI, -0.29 to 0.92)  G1 vs. G2 26 week Differences: -0.06 (95% CI, -6.02 to 5.90), p = 0.492, ES = -0.01 (95% CI, -0.67 to 0.65) | NR  NR |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Reich et al., 2004[84](#_ENREF_84) | G1: Risperidone  0.5 to 8 mg/day  G2: Placebo | CAPS-2 Mean Changes from Baseline Score (SD) G1: -29.6 (31.5) G2: -18.6 (12.3) p=0.015 | NR | NR  NR |
| Resick et al., 2002[3](#_ENREF_3)  Resick et al., 2003[125](#_ENREF_125) Resick et al., 2012[126](#_ENREF_126) | G1: CBT, cognitive processing therapy  G2: CBT, exposure-based therapy (PE)  G3: WL | CAPS  Mean (SD)  G1 Pre-tx: 74.76 (18.77)  G1 Post-tx: 39.08 (31.12)  G1 3 mth FU: 42.21 (30.13  G1 9 mth FU: 42.87 (31.06)  G1 LTFU: 26.00 (23.35)  G2 Pre-tx:76.60 (19.72)  G2 Post-tx: 44.89 (33.52)  G2 3 mth FU: 49.16 (32.86)  G2 9 mth FU: 46.98 (33.68)  G2 LTFU: 25.90 (26.05)G3  Pre-tx: 69.85 (19.57)  G3 Post-tx: 69.26 (18.55)  G3 3 mth FU: 69.26 (18.55)  G3 9 mth FU: 69.26 (18.55)  Posttreatment differences, p<.0001  3 mth FU differences, p<0.0001  9 mth FU differences, p<0.0001  LTFU differences, NS | PSS  Mean (SD)  G1 Pre-tx: 29.55 (8.62)  G1 Post-tx:13.66 (11.05)  G1 3 mth FU: 14.67 (11.79)  G1 9 mth FU:15.13 (12.03)  G1 LTFU: 9.68 (10.38)  G2 Pre-tx: 30.09 (9.18)  G2 Post-tx:17.99 (13.17)  G2 3 mth FU:18.05 (13.78)  G2 9 mth FU: 18.40 (13.98)  G2 LTFU: 9.89 (10.52)  G3 Pre-tx: 28.70 (7.33)  G3 Post-tx: 27.77 (8.12)  G3 3 mth FU: 27.77 (8.12)  G3 9 mth FU: 27.77 (8.12)  Only G1 vs. G2  Posttreatment differences, NS  3 mth FU differences, NS  9 mth FU differences, NS  LTFU differences, p=0.06 | NR  Lost of PTSD Dx at Posttreatment  G1: 53%  G2: 53%  G3: 2.2%  G1 vs. G2 Overtime, NS  LTFU  G1: 81.6  G2: 58.7  G1 vs. G2, NS |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Resick et al., 2015[127](#_ENREF_127), [128](#_ENREF_128) | G1: CPT-C (Includes only the cognitive component of CPT) G2: PCT | PSS-I  Mean (adjusted for pre-tx values at post-tx, 6 month, and 12 month followup) (SE)  G1 Pre-tx: 27.7 (7.4) G1 Post-tx: 23.0 (1.3) G1 6-month followup: 20.0 (1.5) G1 12-month followup: 19.0 (1.4)  G2 Pre-tx: 27.1 (7.0) G2 Post-tx: 23.9 (1.3) G2 6-month followup: 21 (1.5) G2 12-month followup: 19.9 (1.4)  Between group differences at Post-tx: t = 0.53, p = .60 Between group difference at 6-month followup: t = 0.46, p = 0.65 Between group differences at 12-month followup: t = 0.45, p = 0.66 | PCLS-S  Mean (SD for Pre-tx and SE for Post assessments)  Mean (SE)  G1 Pre-tx: 59.3 (10.1)  G1 Post-tx: 47.8 (1.9)  G1 6-month followup: 46.8 (2.0)  G1 12-month followup: 46.1 (2.3)  G2 Pre-tx: 58.5 (10.6)  G2 Post-tx: 51.2 (1.9)  G2 6-month followup: 50.2 (2.0)  G2 12-month followup: 48.6 (2.2)  Slope (SE) and p value for ME regression model of PCLS-S with repeated measures.  G1: -1 (.11), t = -8.98, p < .0001 G2: -.6 (.11), t = -5.49, p < .0001 Difference: -.4 (.16), t = 2.55, p = .012  Between group effect sizes (d): Baseline to posttreatment: -.4 Baseline to 6 months: -.4 Baseline to 1 year: -.3 | NR |
| Rothbaum et al., 1997[45](#_ENREF_45) | G1: EMDR  G2: WL | PSS  Mean (SD)  G1 Pre-tx: 33.3 (8.7)  G1 Post-tx: 14.3 (8.4)  G1 3 mth FU: 9.8 (8.7)  G2 Pre-tx: 39.0 (8.2)  G2 Post-tx: 35.0 (5.9)  Posttreatment G1 vs. G2, p<0.05 | IES  Mean (SD)  G1 Pre-tx: 47.4 (15.0)  G1 Post-tx: 12.4 (11.2)  G1 3 mth FU: 5.7 (5.8)  G2 Pre-tx: 48.9 (8.9)  G2 Post-tx: 45.4 (6.4)  Posttreatment G1 vs. G2, p<0.01 | NR  NR |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Rothbaum et al., 2005[13](#_ENREF_13) | G1: CBT, exposure-based therapy (PE)  G2: EMDR  G3: WL | Data reported in graphs | Data only presented in graphs | NR  Loss of PTSD Dx at Posttreatment:  G1: 95%  G2: 75%  G3: 10%  G1&G2 vs. G3 p<0.001  G1 vs. G2 p=0.108  Loss of PTSD Dx at 6 months f/u:  G1: 94.4%  G2: 73.7%  p=0.185 |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Ruglass et al., 2017 [143](#_ENREF_143) | G1: COPE  G2: Relaspe Prevention  G3: AMCG | CAPS-Severity  Mean (SD)  G1 Pre-tx: 55.38 (16.40)  G1 Post-tx: 37.63 (23.76)  G1 Followup 1 months: 29.50 (27.88)  G1 Followup 2 months: 29.77 (26.14)  G1 Followup 3 months: 28.40 (23.09)  Change at 1 month: -27.12 (95% CI, -35.84 to -18.40), p <0.001  Change at 3 months: -28.31 (95% CI, -36.01 to -20.60), p <0.001  G2 Pre-tx: 57.70 (20.80)  G2 Post-tx: 30.79 (27.54)  G2 Followup 1 months: 29.00 (22.99)  G2 Followup 2 months: 30.40 (22.83)  G2 Followup 3 months: 28.91 (22.91)  Change at 1 month: -25.38 (95% CI, -33.12 to -17.64), p <0.001  Change at 3 months: -26.71 (95% CI, -34.28 to -19.14), p <0.001  G3 Pre-tx: 46.39 (11.07)  G3 Post-tx: 41.89 (24.52)  Change: NR, ns  Treatment X Time interactions at 1-month, p = 0.86  In Group and Between Group Differences at 1 month and 3 months, ns | MPSS-SR  Mean (SD)  G1 Pre-tx: 54.26 (24.60)  G1 Post-tx: 19.40 (17.70)  Change: -42.99 (95% CI, -56.30 to -29.68), p <0.001  G2 Pre-tx: 57.49 (24.33)  G2 Post-tx: 26.80 (20.87)  Change: -31.51 (95% -40.64 to -22.38)  G3 Pre-tx: 50.21 (23.58)  G3 Post-tx: 40.00 (28.10)  Change: NR, ns  Treatment X Time Interaction, p <0.001  Between group differences  G1 vs G3: -34.06 (95%CI -51.36 to -16.75), p <0.001  G2 vs G3: -22.58 (95%CI -36.92 to -8.24), p =0.002  G1 vs G2: -11.48 (95%CI -27.62 to 4.67), p =0.16 | NR  NR |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Sannibale et al. 2013[146](#_ENREF_146) | G1: IT (Integrated CBT for PTSD and AUD)  G2: AS, (CBT for AUD plus supportive counseling) | CAPS-Severity  Mean (SD)  G1 Pre-tx: 68.00 (23.63)  G1 Post-tx: 42.80 (26.45)  G1 Followup 5 months: 40.39 (23.49)  G1 Followup 9 months: 43.30 (28.25)  G2 Pre-tx: 68.07 (21.10)  G2 Post-tx: 46.71 (26.27)  G2 Followup 5 months: 49.71 (22.90)  G2 Followup 9 months: 41.19 (34.17)  Treatment group\*time interactions ns | PDS  Mean (SD)  G1 Pre-tx: 33.07 (10.43)  G1 Post-tx: 21.88 (14.66)  G1 Followup 5 months: 20.88 (13.37)  G1 Followup 9 months: 22.88 (16.68)  G2 Pre-tx: 31.38 (10.43)  G2 Post-tx: 24.18 (14.05)  G2 Followup 5 months: 24.48 (16.00)  G2 Followup 9 months: 20.81 (17.00)  Treatment group\*time interactions ns | Remission NR  Loss of Diagnosis based on CAPS, n (%)  G1 Post-tx:20 (67)  G1 Followup 5 months: 22 (73)  G1 Followup 9 months: 21(70)  G2 Post-tx: 21 (75)  G2 Followup 5 months: 18(64)  G2 Followup 9 months: 21 (75)  Between group differences, β = -0.30, SE = 0.51, p = 0.554 |
| Sautter et al., 2015[131](#_ENREF_131) | G1: SAT  G2: PFE | CAPS  Mean (SE)  G1 Pre-tx: 85.93 (3.31)  G1 Post-tx: 48.33 (3.71)  G1 12 week followup: 44.64 (3.78)  G2 Pre-tx: 82.93 (3.37)  G2 Post-tx: 72.59 (3.79)  G1 12 week followup: 71.93 (3.86)  Treatment X Time Interaction at post-tx, t (80) = 4.95, p <0.0001  Treatment X Time Interaction at 12 week followup, t (80) = 5.41, p <0.0001 | PCL-M  Mean (SE)  G1 Pre-tx: 60.84 (2.12)  G1 Post-tx: 42.16 (2.38)  G1 12 week followup: 39.54 (2.48)  G2 Pre-tx: 60.81 (2.17)  G2 Post-tx: 53.91 (2.48)  G2 12 week followup: 51.77 (2.53)  Treatment X Time Interaction at post-tx, p = 0.0007  Treatment X Time Interaction at 12 week follow, p =0.0006 | Remission/No Longer Met PTSD diagnostic criteria (based on CAPS lower than 45) at followup  G1: 15 (52%)  G2: 2 (7%)  X2 (1) = 11.48, p = 0.0003 (Fisher’s exact test) |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Schnurr et al., 2003[139](#_ENREF_139) | G1: Exposure-based, trauma-focused group therapy (psychoeducation, cognitive restructuring, relapse prevention, and coping skills training)  G2: Present-centered group Therapy (avoided trauma-focused references, cognitive restructuring, and other trauma-focused group therapy components) | CAPS  Mean (SE) G1 Pre-tx: 80.41 (1.45) G1 7 mth FU: 74.00 (1.32) G1 12 mth FU: 72.79 (1.51) Change at 7 mths, p<0.001  Change at 12 mths, p<0.001  G2 Pre-tx: 82.01 (1.44) G2 7 mth FU: 76.03 (1.32) G2 12 mth: 74.82 (1.49) Change at 7 mths, p<0.001  Change at 12 mths, p<0.001  Treatment Effect, p=0.29  Cohort Effect, p=0.01  Treatment X Cohort Effect, p=0.04  PTSD Checklist  Mean (SD)  G1 Pre-tx: 61.84 (0.91)  G1 7 mth FU: 59.70 (0.84)  G1 12 mth FU: 58.78 (0.89)  Change at 7 mths, p<0.01  Change at 12 mths, p<0.01  G2 Pre-tx: 62.60 (0.94)  G2 7 mth FU: 61.03 (0.84)  G2 12 mth FU: 60.00 (0.88)  Change at 7 mths, p>0.05  Change at 12 mths, p<0.05  Treatment Effect, NS  Treatment X Cohort Effect, p=0.05 | NR | NR  NR |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Schnurr et al., 2007[138](#_ENREF_138) | G1: CBT, exposure-based therapy (PE)  G2: PCT | CAPS  Baseline  Mean (95% CI)  G1: 77.6 (74.8 to 80.4)  G2: 77.9 (75.1 to 80.6)  Least Means (95% CI) Immediate posttreatment  G1: 52.9 (47.7 to 58.0)  G2: 60.1 (55.3 to 64.8)  G1 vs. G2, P=.01  3 mth FU G1: 49.7 (44.7 to 54.7)  G2: 56.0 (50.5 to 61.5)  G1 vs. G2, P=.047  6-month G1: 50.4 (45.0 to 55.8)  G2: 54.5 (49.3 to 59.7)  G1 vs. G2, p =.21  Treatment Effect, p=0.03  Treatment X Time, p=0.37 | PCL  Baseline  Mean (95% CI)  G1: 58.2 (56.0 to 60.3)  G2: 57.1 (55.0 to 59.2)  Least Square Means (95% CI)  Immediate posttreatment  G1: 41.6 (38.4 to 44.9)  G2: 48.9 (45.8 to 52.0) G2  G1 vs. G2, p<0.001  3-month  G1: 43.5 (40.2 to 46.7)  G2: 48.8 (45.3 to 52.4)  at posttreatment  G1 vs. G2, p<0.008  6-month  G1: 44.6 (41.2 to 48.1)  G2: 48.5 (45.2 to 51.8)  G1 vs. G2, p =0.049  Treatment X Time, p=0.18 | Total remission, CAPs score <20  G1: 15.2%  G2: 6.9% OR (95% CI): 2.43 (1.10-5.37)  Loss of diagnosis based on CAPS  G1: 41.0%  G2: 27.9%  OR (95% CI): 1.80 (1.10-2.96) |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Schnyder et al., 2011[49](#_ENREF_49) | G1: Eclectic psychotherapy  BEP  G2: WL (Minimal attention) | CAPS  Mean (SD) G1 Pre-tx: 78.6 (16.0) G1 Post-tx: 60.8 (32.8) G1 6 mth FU: 58.1 (30.5)  G2 Pre-tx: 73.4 (19.2) G2 Post-tx: 66.4 (20.0)  Group Effect, p<0.01 | NR | Remission Rates (CAPS score <20) Posttreatment G1: 12.5% (n=2) G2: 0.0% (n= 0)  6-month Followup G1: 18.8% (n=3) G2: 0.0% (n= 0)  Lost of PTSD Diagnosis (CAPS Total Score of <50)  Posttreatment  G1: 12.5% (n=2)  G2: 0.0% (n=0) |
| Simon et al., 2008[174](#_ENREF_174) | G1: Paroxetine  12.5 to 62.5 mg/day  G2: Placebo (  Placebo and 5 additional sessions of PE) | SPRINT Mean (SD) G1 Pre-tx: 16.11 (8.99) G1 Improvement Post-tx: 2.33 (5.24)  G2 Pre-tx: 17.00 (7.65) G2 Improvement Post-tx: 4.57 (7.24)  p=NS | NR | Remission based on having a SPRINT score less than 6 at end point G1: 33% G2: 14%  NR |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Sloan et al., 2012[17](#_ENREF_17) | G1: Sertraline 25 to 200mg/day  G2: Venlafaxiene 37.5 to 375mg/day  Sertraline 25 to 200mg/day | CAPS  Standardized mean gain (95% CI)  G1 Post-tx:3.18 (2.20, 4.16)  G2 Post-tx: -0.14 (-0.39, 0.12)  Condition X Time  -17.96 (95% CI, -13.04, -22.89)  individuals in the WET condition reported sign. Greater decreases in PTSD symptom severity across time than individuals in WL(p<.001)  Hedge’s g (effect size):  Post-tx: 3.49  FU: 2.18 |  | Remission NR  Loss of Diagnosis  G1 Post-tx: 95%  G2 Post-tx: 12%  X2 = 37.66, p <0.001  G1 18 week followup: 100%  G2 18 week followup: 33%  X2 = 22.49, p <0.001 |
| Sonne et al., 2016[186](#_ENREF_186) | G1: WET  G2: WL | NR | HTQ (ITT)  Mean (SE)  G1 Pre-tx: 3.24 (0.04)  G1 Post-tx: 3.02 (0.06)  Difference: 0.22 (0.06), p <0.01, Effect size: 0.54  G2 Pre-tx: 3.18 (0.05)  G2 Post-tx: 3.05 (0.06)  Difference: 0.13 (0.06), p =0.02, Effect size: 0.32  Group difference for difference between pre- and post-treatment ratings: 0.09 (0.08), p = 0.27, Effect size: 0.22  Group differences at follow up: Regression coefficient, B = 0.07 (95% CI, -0.09 to 0.22), Beta-coefficient = 0.06, SE = 0.08, p = 0.40 | Remission NR  Loss of PTSD diagnosis NR |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Spence et al., 2011[30](#_ENREF_30) | G1: CBT-mixed  (Imaginal exposure, Coping skills, Cognitive processing)  G2: WL | NR | PCL-C  Mean (SD)  G1 Pre-tx: 60.78 (10.03)  G1 Post-tx: 44.78 (17.29)  G1 3 mth FU: 43.17 (17.89)  G2 Pre-tx: 57.00 (9.69)  G2 Post-tx: 51.79 (12.51)  G2 3 mth FU: NR  Treatment effect at 8 weeks, p<0.03 | Significant difference between groups at posttreatment for remission on PCL (p<0.01)  Loss of diagnosis based on PCL at 3 months  G1: 61%  G2: NR |
| Stein et al., 2002[80](#_ENREF_80) | G1: Olanzapine  10 to 20 mg  G2: Placebo | CAPS Mean Change from Baseline (95% CI)  G1: -14.8 (SD=14.16) p<.05  G2: -2.67 (SD=10.55) p<0.05 | NR | NR  NR |
| Tarrier et al., 1999[129](#_ENREF_129)  Tarrier et al., 1999[130](#_ENREF_130) | G1: CBT, exposure-based therapy  G2: CBT, cognitive restructuring,  Cognitive Therapy | CAPS Global Severity Mean (SD) G1 Pre-tx: 71.14 (18.98)  G1 Post-tx: 48.24 (30.25) G1 6 mth FU: 52.11 (23.78)  G2 Pre-tx: 77.76 (14.95)  G2 Post-tx: 50.82 (23.99) G2 6 mth FU: 50.21 (24.37)  G1 vs. G2 differences, NS  12-Month Followup G1 Pre-tx: 71.76 (19.59) G1 12 mth FU: 45.16 (28.26)  G2 Pre-tx:76.93 (15.40) G2 12 mth FU: 52.48 (24.09)  G1 vs. G2 differences, NS | IES-I  Mean (SD)  G1 Pre-tx: 23.86 (8.24)  G1 Post-tx: 16.39 (10.04)  G1 6 mth FU: 15.85 (9.26)  G2 Pre-tx: 26.73 (7.80)  G1 Post-tx:17.91 (10.29)  G2 6 mth FU: 17.72 (10.40)  G1 vs. G2 differences, NS  12 Month Followup  G1 Pre-tx:24.68 (7.47)  G1 12 mth FU: 15.67 (9.16)  G2 Baseline: 26.55 (7.78)  G2 12 mth FU: 18.68 (9.24)  G1 vs. G2 differences, NS | NR  Percent of Patients who were no longer PTSD cases  Posttreatment  Overall: 50%  G1: 59%  G2: 42%  6-Months  Overall: 52%  G1: 52%  G2: 52%  12-Months  Overall: 61% |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Tarrier et al., 1999[129](#_ENREF_129)  Tarrier et al., 1999[130](#_ENREF_130)  (continued) |  |  | IES-A  Mean (SD)  G1 Pre-tx: 22.69 (9.24)  G1 Post-tx: 14.89 (9.09)  G1 6 mth FU: 17.70 (10.74)  G2 Pre-tx: 26.21 (7.55)  G2 Post-tx: 19.61 (10.09)  G2 6 mth FU: 18.31(9.66)  G1 vs. G2 differences, NS  IES-A  12 Month Followup  G1 Pre-tx: 23.00 (9.36)  G1 12 mth FU:18.00 (11.36)  G2 Pre-tx:26.21 (7.93)  G2 12 mth FU: 20.68 (10.97)  G1 vs. G2 differences, NS  Penn Inventory  Mean (SD)  G1 Pre-tx: 47.28 (10.96)  G1 Post-tx: 34.43 (14.69)  G1 6 mth FU: 41.78 (12.50)  G2 Pre-tx: 46.52 (12.98)  G2 Post-tx: 36.09 (15.46)  G2 6 mth FU: 37.24 (15.76)  G1 vs. G2 differences, NS  12 Followup  G1 Pre-tx: 47.52 (10.79)  G1 12 mth FU: 41.04 (14.08)  G2 Pre-tx: 47.03 (13.45)  G2 12 mth FU: 38.39 (15.12)  G1 vs. G2 differences, NS |  |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Taylor et al., 2003[133](#_ENREF_133) | G1: CBT, exposure-based therapy  G2: EMDR  G3: Relaxation Training | CAPS  Data only reported in graphs  Completers  G1 Pre-Post changes, p<0.005 G2 Pre-Post changes, p<.001  G3 Pre-Post changes, p<0.005  Intent to Treat  No significant differences | PTSD Symptom Severity Scale (part of PTDS)  Intent to Treat Sample  3 treatments did not differ (p>0.05) | NR  NR |
| ter Heide et al., 2016[43](#_ENREF_43) | G1: EMDR  G2: Stabilisation | CAPS  G1 vs. G2, d = -0.04, NS | HTQ, DSM-IV  G1 vs. G2, d = 0.20, NS  HTQ, total  G1 vs. G2, d = 0.29, NS | Remission  CAPS Severity change  N (%)  Improvement (> 10 points)  G1:13/32 (40.6)  G2: 13/31 (41.9)  Loss of Diagnosis based on CAPS  N (%)  Posttreatment  G1 Post-tx:6 (19)  G2 Post -tx: 9 (29)  X2 (df) = 0.08 (1), p = 0.78 |
| Tucker et al., 2001[65](#_ENREF_65) | G1: Paroxetine  20 to 50mg/day  G2: Placebo | CAPS-2 Adjusted Mean Differences (95% CI), G1 vs. G2 -10.6 (-16.2 to -5.0)  TOP-8 Adjusted Mean Differences (95% CI), G1 vs. G2 -3.8 (-5.6 to -1.9) | DTS  Adjusted Mean Differences (95% CI)  G1 vs. G2 -12.6 (-18.8 to -6.4) p<0.001 | CAPS-2 total score <20  29.4% vs. 16.5% achieved remission; OR, 2.29; 95% CI, 1.24 to 4.23; p=0.008  NR |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Tucker et al., 2003[175](#_ENREF_175)  Tucker et al., 2004[176](#_ENREF_176) | G1: Citalopram  20 to 50 mg/day  G2: Sertraline  50 to 200 mg/day  G3: Placebo | CAPS  Mean (SD) G1 Pre-tx: 91.0 (10.58)  G1 Post-tx: 60.28 (26.15)  G2 Pre-tx: 83.91 (17.28)  G2 Post-tx: 42.09 (29.09)  G3 Pre-tx: 94.20 (11.9) G3 Post-tx: 55.5 (29.07)  Between group differences, NS | IES  G1 Pre-tx: 50.04  G1 Post-tx: 24.65  G2 Pre-tx: 46.26  G2 Post-tx: 17.16  G3 Pre-tx: 53.8  G3 Post-tx: 20.57  Between group diffrences, p value NR | NR  NR |
| Tucker et al., 2007[78](#_ENREF_78) | G1: Topiramate  25 to 400mg/day; given 2 times a day  G2: Placebo | CAPS  Mean Percentage Change (SD) G1: -59.5 (35.9) G2: -45.5 (34.3) p=0.227  TOP-8  Mean Percentage Change (SD)  G1: -67.9 (30.0)  G2: -41.6 (37.8)  p= 0.023 | DTS  Mean Percentage Change (SD)  G1: -54.1(35.8)  G2: -32.3(34.8)  p=0.065 | CAPS score <20, N  G1: 8  G2: 4  p=0.295  NR |
| Van Dam et al., 2013[262](#_ENREF_262) | G1: SWT plus TAU  G2: TAU (regular intensive  treatment program for SUD based on CBT) | NR | PDS  Mean (SD)  G1 Pre-tx: 30.4 (9.7)  G1 Post-tx: 17.6 (12.0)  G1 Followup 3 months: 23.5 (14.8)  G2 Pre-tx: 28.3 (10.7)  G2 Post-tx: 24.3 (9.1)  G2 Followup 3 months: 21.7 (9.4)  Treatment X time Interaction, F(3,34) = 1.92, p = 0.132, η2 = 0.059 | Full and Partial Remission (Remitted based on SCID), n (%)  G1 Post-tx:9.2(48.2)  G2 Post-tx: 1.8 (12)  Between group difference not reported  Full PTSD Remission, (Remitted based on SCID), n (%)  G1 Post-tx: 2 (22)  G2 Post-tx: 1.2 (10)  Between-group difference in PTSD diagnostic status (p = 0.06), less patients were diagnosed with PTSD in G1 vs. TAU  NR |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| van den Berg et al., 2015[16](#_ENREF_16) | G1: PE  G2: EMDR  G3: WL | CAPS  Mean (SD or 95% CI)  G1 Pre-tx:69.6 (14.9)  G1 Post-tx: 37.8 (31.2 to 44.3)  G1 6 month FU: 36.7 (30.1 to 43.4)  G1 vs. G3 Post-tx, Effect size: 0.78  t = -3.84, p <0.001  G1 vs. G3 6 month, Effect size: 0.63  t = -3.10, p =0.002  G2 Pre-tx: 72.1 (17.6)  G2 Post-tx: 40.3 (33.6 to 47.1)  G2 6 month FU: 38.8 (31.9 to 45.6)  G2 vs. G3 Post-tx, Effect size: 0.65  t = -3.26, p =0.001  G2 vs. G3 6 month, Effect size: 0.53  t = -2.66, p =0.009  G3 Pre-tx: 68.1 (15.9)  G3 Post-tx: 56.5 (49.5 to 63.6)  G3 6 month FU: 51.9 (44.9 to 58.9)  G1 vs. G2 differences NS | PSS-SR  Mean (SD or 95% CI)  G1 Pre-tx: 28.5 (8.0)  G1 Post-tx: 16.1 (13.1 to 19.1)  G1 6 month FU: 16.4 (13.4 to 19.4)  G1 vs. G3 Post-tx, Effect size: 0.88  t = -4.33, p <0.001  G1 vs. G3 6 month, Effect size: 0.70  t = -3.46, p =0.001  G2 Pre-tx: 30.3 (7.8)  G2 Post-tx: 16.1 (12.9 to 19.2)  G2 6 month FU: 16.2 (13.0 to 19.3)  G2 vs. G3 Post-tx, Effect size: 0.85  t = -4.26, p <0.001  G2 vs. G3 6 month, Effect size: 0.70  t = -3.51, p =0.001  G3 Pre-tx: 27.7 (8.9)  G3 Post-tx: 25.8 (22.5 to 28.9)  G3 6 month FU: 24.1 (20.9 to 27.4)  G1 vs. G2 differences NS | Full Remission based on CAPS (score <20)  N (%)  G1 Post-tx: 15 (28.3)  G2 Post-tx:9 (16.4)  G3 post-tx:3 (6.4)  G1 vs. G3 Post-tx, OR = 3.41, p = 0.006  G2 vs. G3 Post-tx, OR = 3.92, p < 0.001  G1 6 month FU: 14(26.4)  G2 6 month FU: 8 (14.5)  G3 6 month FU: 3 (6.4)  G1 vs. G3 6 month FU, OR = 3.01, p = 0.003  G2 vs. G3 6 month FU, OR= 2.76, p = 0.002  G1 vs. G2 differences NS  Loss of Diagnosis based on CAPS  N (%)  G1 Post-tx:30 (56.6)  G2 Post-tx:33 (60.0)  G3 post-tx: 13 (27.7)  G1 vs. G3 Post-tx, OR = 3.01, p = 0.003  G2 vs. G3 Post-tx, OR = 2.76, p = 0.002  G1 6 month FU:31 (58.5)  G2 6 month FU: 31 (56.4)  G3 6 month FU:15 (31.9)  G1 vs. G3 6 month FU, OR = 3.01, p = 0.003  G2 vs. G3 6 month FU, OR= 2.76, p = 0.002  G1 vs. G2 differences NS |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| van der Kolk et al., 1994[63](#_ENREF_63) | G1: Fluoxetine  20 to 60mg/day  G2: Placebo | CAPS Difference in Improvement G1 vs. G2= 12.59  ANCOVA Results F = -12.59, t = -2.67, p=0.0106 | NR | NR  NR |
| van der Kolk et al., 2007[47](#_ENREF_47) | G1: EMDR  G2: Fluoxetine  10 to 60 mg/day  G3: Placebo | CAPS  Mean (SD) (Post-tx & FU - ITT)  G1 Pre-tx (1 mth CAPS): 71.7 (11.9)  G1 Pre-tx (1 wk CAPS): 69.4 (12.7)  G1 Post-tx: 32.55 (22.5)  G1 FU: 25.79 (21.61)  G2 Pre-tx (1 mth CAPS): 75.9 (15.6)  G2 Pre-tx (1 wk CAPS): 73.7 (13.4)  G2 Post-tx: 42.67 (22.11)  G2 FU: 42.12 (15.83)  G3 Pre-tx (1 mth CAPS): 74.5 (12.5)  G3 Pre-tx (1 wk CAPS): 70.3 (13.0)  G3 Post-tx: 43.55 (22.6)  G3 FU: NA  Posttreatment  Treatment effect, NS  G1 vs. G3, NS  G2 vs G3, NS  G1 vs. G2, NS  Followup  G1 vs. G2, p=0.005 | NR | % asymptomatic, defined as CAPS <20 G1: 28 G2: 13 G3: 10 G1 vs. G2, p=0.17 G1 vs. G3, p=0.09 G2 vs. G3, p=0.72 6-month post-treatment f/u (intent-to-follow) G1: 58%  G2: 0% G3: NA p<0.001  Lost of PTSD Diagnosis, %  G1: 76  G2: 73  G3: 59  G1 vs. G2, p=0.82  G1 vs. G3, 0.16  G2 vs. G3, 0.23 (G2/3)  6-month post-treatment f/u (intent-to-follow)  G1: 88%  G2: 73%  G3: NA  p= 0.20 |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| van der Kolk et al., 2016[162](#_ENREF_162) | G1: Neurofeedback  G2: WL | CAPS Mean (95% CI) G1 Pre-tx: 79.45 (72.86 to 86.04)  G1 Post-tx: 42.95 (34.1 to 51.8)  G1 1 month FU: 39.1 (29.69 to 48.51)  G1 Pre-tx to 1 month difference: -40.42 (-48.67 to -32.12)  d = -2.33  G2 Pre-tx: 76.24 (69.13 to 83.36)  G2 Post-tx: 66.49 (57.39 to 75.6) G2 1 month FU: 65.46 (55.83 to 75.1) G2 Pre-tx to -1 month difference: -10.78 (-19.1 to -2.48) d = -0.62  Difference between groups at 1 month: -29.6 (-41.33 to -17.87)  d = -1.71  Treatment x time interaction: b = -10.45, t = -5.1, p <0.001 | DTS  Mean (95% CI) G1 Pre-tx: 67.28 (57.55 to 77.00)  G1 Post-tx: 44.19 (35.76 to 52.63)  G1 1 month FU: 36.5 (27.4 to 45.6)  G1 Pre-tx to post-tx difference: -23.04 (-29.68 to -16.48)  d = -0.92  G1 Post-tx to FU difference: -7.69 (-9.89 to -5.49)  d = -0.31  G2 Pre-tx: 62.97 (52.47 to 73.48)  G2 Post-tx: 58.21 (49.26 to 67.16)  G2 1 month FU: 56.62 (47.09 to 66.15) G2 Pre-tx to post-tx difference: -4.76 (-11.6 to 2.07)  d = -0.19  G2 Post-tx to FU difference: -1.59 (-3.87 to 0.69)  d = -0.06  Difference between groups at post-tx: -18.32 (-27.82 to -8.82)  d = -0.73  Difference between groups at post-tx to FU: -6.11 (-9.27 to -2.94)  d = -0.24  treatment x time interaction: b = -1.52, t = -3.89, p <0.001 | Loss of PTSD Diagnosis, n (%)  G1 post-tx: 72%  G2 post-tx: 32%  G1 1 month FU: 58% G2 1 month FU: 10%  Posttx between group difference chi-sq: 7.38, p=0.007 Baseline between group difference chi-sq: 9.47, p = 0.002 |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| van Emmerik et al., 2008[40](#_ENREF_40) | G1: CBT-Mixed  Psychoeducation, prolonged exposure, imaginal exposure, exposure in vivo, cognitive exposure  G2: SWT  G3: WL | NR | IES  Mean (SD)  G1 Pre-tx: 46.40 (12.32)  G1 Post: 32.00 (20.32)  G1 FU: 33.68 (22.18)  G2 Pre-tx: 47.87 (13.82)  G2 Post-tx: 34.32 (22.58)  G2 FU: 33.68 (24.63)  G3 Pre-tx: 49.14 (14.66)  G3 Post-tx: 45.66 (13.65)  G3 FU: 46.63 (13.17)  Group X Time Effect  G1 vs G2, p=0.62  G1+G2 vs G3, p<0.01 | NR  NR |
| Wells et al., 2014[19](#_ENREF_19) | G1: Metacognitive therapy  G2: PE  G3: WL | NR | PDS  Mean (SD) G1 Pre-tx: 37.2 (8.93)  G1 Post-tx: 10.4 (6.98)  G1 3 month FU: 14.5 (16.2)  Mean difference, post-tx: 26.8 (SE, 2.2), p <.005, (95% CI, 21.82 to 31.78)  G2 Pre-tx: 32.80 (8.85)  G2 Post-tx: 18.3 (13.31)  G2 3 month: 16.5 (9.47)  Mean difference, post-tx: 14.5 (SE, 4.61), p = 0.01, (95% CI, 0.08 to 24.92)  G3 Pre-tx: 38.3 (8.74) G3 Post-tx: 39.2 (8.85) G3 3 month: NA  Mean difference, post-tx: -0.9 (SE, 0.75), p > 0.05, (95% CI, -2.60 to 0.80) | Loss of Diagnosis based on SCID-I/P  G1: 1 (10%)  G2:3 (33%)  G3:NR  Remission NR |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Wells et al., 2014[19](#_ENREF_19)  (continued) |  |  | Treatment X Time Interaction: F=21.70, p < .0005  Hedge's g: G1 Pre-Post: 3.52 G2 Pre-Post: .91 G1 Pre-FU: 1.23 G2 Pre-FU: 1.08  ANCOVA group effect: F = 25.79, p < .0005 G1 vs G3 Pre-Post: 28.16 (3.95), p < .0005, (95% CI, 18.05 to 38.28) G2 vs G3 Pre-Post: 17.71 (4.09), p = .001, (95% CI, 7.25 to 28.16) G1 vs G2 Pre-Post: 10.46 (4.05), p = .05, (95% CI, 0.13 to 20.79)  ANCOVA group effects at followup  G1 vs. G2: F = 0.16, p = 0.69  IES  Mean (SD) G1 Pre-tx: 53.3 (8.87)  G1 Post-tx: 9.9 (9.69)  G1 3 month FU: 17.1 (19.31)  Mean Difference, post-tx: 43.4 (SE, 2.77), p<0.0005, (95% CI, 37.13 to 49.68)  G2 Pre-tx: 51.2 (8.16)  G2 Post-tx: 23.7 (16.28)  G2 3 month followup: 22.1 (16.21.19)  Mean Difference, post-tx: 27.5 (SE, 5.91), p = 0.001, (95% CI, 14.13 to 40.87) |  |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Wells et al., 2014[19](#_ENREF_19)  (continued) |  |  | G3 Pre-tx: 52.3 (12.98) G3 Post-tx: 51.3 (13.43) G3 3 month followup: NA Mean Difference, post-tx:1.0. (SE, 3.12), p >.05, (95% CI, -6.06 to 8.06)  Treatment X Time: F = 26.3, p < 0.005  Hedge's g: G1 Pre-Post: 4.52 G2 Pre-Post: 1.34 G1 Pre-FU: 2.39 G2 Pre-FU: 1.17  ANCOVA group effect: F = 28.81, p < 0.0005 G1 vs G3 Pre-Post: 41.43 (SE, 5.60), p < 0.0005, (95% CI, 27.59 to 56.26) G2 vs G3 Pre-Post: 27.02 (SE, 5.60), p <0.0005, (95% CI, 12.68 to 41.36) G1 vs G2 Pre-Post: 14.9 (SE, 5.62), p = 0.04, (95% CI, 0.52 to 29.28)  ANCOVA group effects at followup  G1 vs. G2: F = 0.62, p = 0.44 |  |
| Yeh et al., 2011[79](#_ENREF_79) | G1: Topiramate  25 to 200mg/day  G2: Placebo | CAPS Mean(SD) G1 Pre-tx: 78.76 (12.64) G1 Post-tx: 30.41 (30.90)  G2 Pre-tx: 66.14 (22.63) G2 Post-tx: 35.78 (33.76)  Between Group Change, p=0.49 | NR | NR  NR |

| Author, Year | Intervention Groups | Clinician Administered | Self-Administered | Symptom Remission  Loss of PTSD Diagnosis |
| --- | --- | --- | --- | --- |
| Zlotnick et al., 2009[56](#_ENREF_56) | G1: Seeking Safety;  G2: Usual care  Psychoeducational group and individual case management and drug counseling | CAPS  Mean difference (95% CI)  -2.30 (-13.81, 9.21) | NR | NR  Percentage that Loss PTSD Diagnoiss based on CAPS  Post-tx  G1: 52  G2: 45  3 mth FU  G1: 61  G2: 57  6 mth FU  G1: 57  G2: 62 |
| Zohar et al., 2002[72](#_ENREF_72) | G1: Sertraline  50 to 200 mg/day  G2: Placebo | CAPS-2 Mean Change from Baseline (SD)  G1: -18.7 (6.7) G2: -13.5 (6.6) Between Group Change, p=0.530 | NR | NR  NR |

AMCG = active monitoring control group; ANOVA = analysis of variance; ANCOVA = analysis of covariance; CAPS = Clinician-administered PTSD Scale; CBT = Cognitive behavioral therapy; CI = confidence interval; CT = cognitive therapy; CPT = cognitive processing therapy; CPT-SA = Cognitive Processing Therapy for Sexual Abuse Survivors; DTS = Davidson Trauma Scale; EMDR = Eye movement desensitization and reprocessing; FU = Folow-up; HLS = health information control condition; IES = Impact of Event Scale; IRT = imagery rehearsal therapy; mg = milligram; MVA = motor vehicle accident; NA = not applicable; NF = Neurofeedback; NR= not reported; NS = not significant; OR = odds ratio; PCL-C =Posttraumatic Stress Disorder Checklist-Civilian; PCL-M = Posttraumatic Stress Disorder Checklist-Military; PCLS = Posttraumatic Stress Disorder Checklist Scale; PDS = Posttraumatic Diagnostic Scale; PE= prolonged exposure; PTSD = post-traumatic stress disorder; Pre-tx = pretreatment; Post-tx = Posttreatment; PSS= PTSD Symptom Scale; PSS-SR= PTSD Symptom Scale-Self-report; PTSD= Post-Traumatic Stress Disorder; RMANOVA, repeated measures analysis of variance; SCID =; SD = standard deviation; SE = standard error; SI-PTSD or SIP= Structured Interview for PTSD; SPRINT= Short PTSD Rating Interview; SSRIs = Selective serotonin re-uptake inhibitors or serotonin-specific reuptake inhibitor; STAIR = Skills Training in Affect and Interpersonal Regulations; SWT = strutured writing therapy; TOP-8 = Treatment Outcome PTSD Scale; VRET = virtual reality exposure therapy.